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ABSTRACT
IN VITRO DRUG DELIVERY BASED ON A POROUS MEMBRANE-BASED
AQUEOUS-ORGANIC PARTITIONING SYSTEM AND ITS ENHANCEMENTS
THROUGH MOUSE SKIN

by
Qiuxi Fan
Novel approaches for transdermal drug delivery (TDD) based on a porous membranebased aqueous-organic partitioning system have been investigated and successful
deliveries were observed. Doxycycline hydrochloride (HCl), a polar antibiotic drug with
a relatively large molecule weight (M-VV: 480.1) was studied as a basic model agent. Its
controlled release using this technique was studied first. Satisfactory release profiles
demonstrate the practical potential of such a system to achieve useful controlled release
rates. The enhancer linoleic acid was essential to successful release using a mouse skin
beneath a porous polymeric membrane. The transport rates of smaller molecules e.g.,
caffeine and nicotine from the same system without any enhancer were very high.
Iontophoretic TDD was studied next using a porous polymeric conducting membrane of
polyaniline (PANi). Doxycycline HCl, lidocaine HCl (MW: 271) and caffeine (MW:
194) in their aqueous solutions were model agents. Excellent release profiles were
achieved; the conducting PANi membrane appeared to be capable of not only replacing
the Ag part of AglAgCl electrode system but also providing an additional control over
agent transport rate. Aqueous-organic partitioning system was tested with this novel
technique as well. Because of the rather low porosity of synthesized PANi membrane,
such a system did not yield a high release rate. The transport rates through polymeric
membrane alone were accurately predicted using simplified mass transport models for

both iontophoretic and non-iontophoretic systems. Finally, a further application of this
new technique was investigated using a thermo-sensitive TDD system. A hydrophilic
porous PVDF membrane immobilized with a thermo-sensitive polymeric gel, poly(Nisopropylacrylamide) (PNIPAAM)-co-2mol% acrylic acid (AA), demonstrated its
release-"on/off' switch function: at normal skin temperature, no release of doxycycline
HCl through the skin occurred; under fever condition, certain amount of this antibiotic
accumulated beneath the skin.
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CHAPTER 1
INTRODUCTION

1.1 Background: Porous Membrane-Based Aqueous-Organic Partitioning System
Membrane-based reservoir systems for controlled release have been extensively studied
for a wide range of therapeutic applications, from oral formulations, transdermal patches
to implants (Borodkin et al., 1975; Chien, 1982; Langer, 1990). Such a membrane system
usually contains a reservoir for the agent sealed by a rate controlling polymeric
membrane/film (Kydonieus, 1980). The diffusion of agent is first through the membrane
then entering the targeted site. The first patent about a microporous membrane-bound
reservoir device was obtained by Zaffaroni (Zaffaroni, 1976a), in which a gel, liquid or
sol agent carrier with a limited solubility of the agent for release is utilized in the
reservoir. A membrane wall, either porous or nonporous, is sealed beneath the reservoir;
the membrane permeability is lower than that in the reservoir so that the ratio of the agent
release rate through the reservoir to that through the membrane can vary based on
different liquids in the reservoir and the pore (for porous membranes). However, the
membrane properties (porosity, tortuosity, thickness), the agent concentration and the
transport through the pore phase are major factors controlling the release rate.
A novel membrane-based controlled release system using aqueous-organic
partitioning was intensely studied by Farrell and Sirkar (Farrell et al., 1997, 1999, 2001).
This new device employs the agent's partitioning between an aqueous solution and an
organic solution as a rate-controlling mechanism. The system consists of a reservoir
containing the agent in an organic solution surrounded by a microporous membrane/film

1

2

with pores filled with aqueous liquid, or vice versa, aqueous solution in reservoir while
organic liquid fills the pores. The partitioning of the agent takes place between the
organic solution and the aqueous one at the interface of the reservoir and the mouth of the
membrane pore. Since partitioning has replaced diffusion as the driving force in a large
part for this device, longer term release at a constant rate (zero order) can be fulfilled by
using an agent solution of high concentration in the reservoir. If a suspension of the agent
is used in the reservoir, an extended zero order release can also be achieved, which
overcomes the problem of short period of constant release often achieved by two other
more commonly used means of controlled release: injection and ingestion.
In Farrell and Sirkar's study (Farrell et al., 1997, 1999, 2001), the reservoir is
filled with either a pure agent liquid or an agent liquid of high concentration in an organic
solvent (for organic agents). Water or an aqueous solution with a lower solubility for an
agent is filled in the membrane pores in order to possess a very high aqueous-organic
partition coefficient. This configuration greatly decreases the agent concentration in the
aqueous pore phase and therefore reduces the rate of agent release; therefore an extended
delivery is achieved. In another case, if the reservoir is filled with the agent in a
concentrated aqueous solution, and an immiscible organic solvent is in the pore, the
reservoir contains either pure agent or a concentrated agent solution, and therefore
aqueous-organic partitioning is employed to reduce drastically the agent driving force for
diffusion cross the membrane. Again, extended release is achieved. Figure 1.1 illustrates
such a device and the role of partition on the diffusion through the membrane (Farrell,
1996; Farrell et al., 1997).

3
Membrane

Pail it ion ..coefficient
K

--

Concentration of agent in organic phase
Concentration of agent m aqueous phase

(a) the partition coefficient i 1.
Partitioning hi ii no effect on the
agenlt concentration gradient in
the liquid-filled membrane
pores
Reservoir Membrane

(b) a high partition coefficient
reduces the driving force for
diffusion through the liquid fined membrane pores

Reservoir

Me

m

brane

(e) a tow partition coefficient
increases the driving force for
diffusion across the liquid filled
membrane pores

Figure 1.1 The role of aqueous-organic partitioning on the diffusion through membrane
pores filled with liquid (Farrell, 1996).

Scopolamine delivery system patented by Urquhart et al. (Urquhart, 1977, 1981)
employ a mineral oil/polyisobutylene mixture with a very low solubility of agent
scopolamine as the reservoir carrier and mineral oil filled in the pores of a microporous
membrane. However, aqueous-organic partitioning is not applied. Several other
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researchers also mentioned the existence of partitioning in nonporous membrane systems
(Flynn et al., 1972; Theeuwes et al., 1976; Zaffaroni, 1976b, 1976a; Urquhart, 1977,
1981); however, it is Farrell and Sirkar who concentrated on demonstrating aqueousorganic partitioning as a means to control the release of agent from the system. This type
of device can be used as a patch, stick-on, or an implant for drugs, fragrances, etc.
without the complications of conventional devices such as drug stability during loading in
a polymer, solvent processing in wet phase inversion, changing the polymer to certain
shapes, etc. Such a system would achieve great flexibility in the release rate of the agent
with the enormously different selections of the solute/solvent/membrane configuration.

1.2 Does It Work in Transdermal Drug Delivery (TDD) Area?
Farrell and Sirkar's study showed the feasibility and potential for polymeric microporous
membrane-based aqueous-organic partitioning system as controlled release devices, and
also presented fundamental information on the release rates of the agent (Farrell, 1996).
They investigated the release of an agent in the reservoir as a pure liquid using toluene
diffusing across water-filled pores as well as agent partitioning in two cases: between an
organic reservoir solution and water-filled pores and between an aqueous reservoir
solution and organic-filled pores. The agent for the former system was benzoic acid, and
the reservoir solvents were decanol and octanol; while for the latter one, aqueous nicotine
was in the reservoir and pores were filled with mineral oil. They also studied the case of
suspension in the reservoir and simultaneous release of two agents using caffeine and
nicotine (Farrell et al., 1997, 2001). Their results showed that partitioning-controlled
release system using a suspension in the reservoir can be fulfilled if the dissolution rate of
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the agent into the reservoir is faster than that of transport through the membrane pores,
and the aqueous-organic partition coefficient of an agent can be used to control its release
rate from its concentrated solution of liquid in the reservoir. The time of extended release
(zero-order) is a function of both the partition coefficient and the total amount of agent in
the reservoir phase. The rate of the release is also affected by the physical characteristics
of the microporous membrane. Farrell and Sirkar concluded that "when the aqueousorganic partition coefficient and the total amount of agent in the reservoir are large,
partitioning will hardly affect the concentration in the reservoir, the reservoir will serve
as an 'infinite reservoir' for the agent for an extended period of time, the agent's
concentration at the aqueous/organic interface at the pore mouth will remain essentially
constant, and zero-order release will be achieved for a period of time." (Farrell et al.,
1997) They also indicated that "the duration of zero-order release was extended by the
introduction of a suspension into the reservoir. If dissolution into the solvent is fast
relative to diffusion out of the reservoir, zero-order release is extended due to the
unchanging reservoir concentration." (Farrell et al., 1997) Based on their experimental
results and theoretical justifications, it seems that aqueous-organic partitioning-based
controlled release system would satisfy the demand of delivering an agent constantly as
long as necessary. Therefore, it is the rationale of further work based on this system in
this dissertation.
Farrell and Sirkar's work focused on some small molecules e.g., benzoic acid
(MW: 122), nicotine (MW: 162) and caffeine (MW: 194), releasing from different
polymeric microporous membrane based on aqueous-organic partitioning system. Will
the transport of these smaller molecules through a composite of polymeric and skin
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membranes be high enough to match the dose requirement of a particular disease? In
addition, molecules of considerable interest are often larger, more complex and
frequently polar, and therefore difficult to transport through the skin. It is certainly true of
the broad-spectrum antibiotic, doxycycline hydrochloride (HCl) of molecular weight
480.l, which is licensed for the prophylaxis and treatment of malaria, acne and Reiter
syndrome (Perkins et al., 1999). It would be of considerable interest to explore whether
the reservoir-based technique based on the relatively simple aqueous-organic partitioning
through a porous membrane could be employed in a skin patch to deliver important
antibiotics e.g., doxycycline HCl, the molecular weight of which is almost 500; such a
high molecular weight (MW) was considered for quite some time to be an upper limit for
transdermal drug delivery (Bos et al., 2000). In this context, transdermal drug delivery of
doxycycline HCl using aqueous-organic partitioning is considered demanding. Such a
goal has been explored in a stepwise fashion first to examine whether this polymeric
porous membrane-based aqueous-organic partitioning system works in transdermal drug
delivery (TDD) area.
Transdermal drug delivery has been investigated around the world for several
decades. Many drugs such as scopolamine, nitroglycerin, estradiol etc. have been
successfully administrated by TDD system. Compared with other drug administrations,
TDD provides rapid onset and relative reliability. Sustained and constant plasma level
can be achieved without generating patient discomfort (Chong et al., 1989).
For skin membrane, the fundamental part of TDD, there are three layers:
epidermis, dermis, and subcutaneous as shown in Figure 1.2 (Singh et al., 1994). The
uppermost layer of the epidermis i.e., the stratum corneum (SC) is the toughest barrier for
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drug delivery because of its rigid, brick-shaped structure. For an agent like doxycycline
HCl having a MW of almost 500 D to go through the skin, the need for a certain amount
of enhancement to improve its delivery is obvious.

apendgl

intercellular

epidermis
dermis

blood

vessels
subcutaneous
rat

Figure 1.2 Schematic of skin structure (Adapted from Singh et al., 1994).

1.3 Enhancements to Improve Drug Delivery through a Skin

The enhancement for TDD is to employ an innocuous physical or chemical means to
(Smith et al., 1995) increase the solubility of the drug in SC reversibly in order to
facilitate diffusion of the agent through the barrier layer i.e., SC to the vasculature (Smith
et al., 1995). Both chemical and physical enhancement have been tried to facilitate the
transportation of the agent through skin.
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1.3.1 Chemical Enhancements

For chemical enhancements, the basic requirements of their properties are (Smith et al.,
1995):
1. It should be specific without a pharmacological action of its own;
2. It should act promptly with a predictable duration and reversible effect;
3. It should be compatible with the agent and other components in the formulation
and be chemically and physically stable;
4. It should be colorless, odorless, tasteless and nontoxic, nonallergenic, nonirritant.
Amide, terpene, fatty acids, etc. are mostly used chemical enhancers.
1.3.2 Iontophoresis as a Means of Physical Enhancement

Iontophoresis, ultrasound, laser light, heat, etc. are generally used as physical enhancers.
Among these, the iontophoretic technique, with its flexibility (different electrode
materials, choices of current density, combination with other enhancements such as
chemical enhancers, etc.) and outstanding releasing profile, has been the most
investigated physical enhancement technique. In this dissertation work since the role of a
polymeric membrane is focused on the TDD field as well, iontophoresis combined with a
conducting polymeric membrane would not only be of great interest but could bring more
options to the active TDD field.
The use of electrical current in drug delivery was first proposed in the middle of
eighteenth century. The nineteenth century witnessed significant progress made by
Hermann Munk, who first observed the systemic effects of iontophoresis in 1879, by
Stephan Leduc, who first used iontophoretic technique, and by other scientists
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(Helmstadter, 2001). The term "iontophoresis" is believed to have been introduced first
by Fritz Frankenhauser (Helmstadter, 2001).
There are several advantages of iontophoretic TDD. First of all, it is a noninvasive way to deliver a drug into the body where great pain is eliminated without
mechanical penetration (such as injections) and disruption of the skin. Another advantage
is that drugs can be delivered either locally or systemically without potential systemic
side effects. As the iontophoretic TDD is controlled by the current, the third advantage is
that it can accurately control the timing of drug delivery (Rhodes III, 2002).
As a non-invasive TDD method, iontophoresis applies electrical current to deliver
solubilized drugs through the skin to either the underlying tissue (local area) or capillaries
and then to the whole circulating system (systemically). Two electrodes immersed in a
drug solution and a voltage applied between the two electrodes have the drug (in the form
of charged ions) moved from the donor part into the skin as shown in Figure l.3
(Burnette, 1989). The positively charged electrode i.e., the anode, will attract the drug
ions with negative charge, while the negatively charged electrode i.e., the cathode will
attract the positively charged ions. Usually silver/silver chloride (Ag|AgCl) electrodes are
used in such a system.
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Figure 1.3 Schematic of principle of iontophoresis (Adapted from Burnette, 1989).

For transdermal drug delivery, there are three general passive diffusion pathways
for a drug going through the skin: transcellular, intercellular and transappendageal
(Kanikkannan, 2002). The major route of iontophoresis transport is believed to be appendageal pores including the sweat ducts and hair follicles, which was proved by the
investigations of several groups (Burnette, 1989; Singh et al., 1994; Kanikkannan, 2002).
As to the pathway of the current facilitation, it is believed that the sweat ducts and glands
are the major contributors (Grimnes, 1984), while for convective flow, hair follicles are
the main pathway (Burnette, 1989; Singh et al., 1994; Kanikkannan, 2002). Figure l.2
shows a schematic pathway of iontophoresis as well (Singh et al., 1994).
Figure l.4 is a typical experimental setup for in vitro iontophoretic TDD study
using side-by-side diffusion cell (Panchagnula et al., 2000).
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Figure 1.4 Schematic of an iontophoretic TDD system (Modified from Panchagnula et
al., 2000).

The system of AgIAgCl electrodes are mostly used for iontophoretic study. Other
materials such as sodium tungstate, graphite, transition metal dichalcogenide, prussian
blue and polypyrrole could also be used as alternative electrodes (Banga, 1998). As
desirable electrodes, they should possess good conductivity, flexible shape to match the
skin surface, and most of all, minimal changes of pH (Panchagnula et al., 2000). Phipps'
group studied platinum as anode and found the pH of donor solution changed from 5.9 to
2.6 resulting from the oxidation of water, while there was no such change for the
Ag|AgCl set (Phipps et al., 1989).
However, not all agents are suitable for the application of iontophoretic TDD.
Only water-soluble drugs of molecular weight under 10,000 ("10,000 Dalton Rule") are
amenable to delivery (Wang et al., 2003). In addition, some patients may get redness,
burning, and/or itching at the drug administration site. Besides, a stable power supply in a
small size is also a big concern. Iontophoresis is still very promising for TDD. The first
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pre-filled iontophoretic TDD patch for local anesthesia has been approved by FDA and
will be available in the market soon (Kalia et al., 2004).

1.4 Application with Porous Conductive Membrane

As the transdermal delivery of doxycycline HCl through microporous polymeric and skin
membranes via aqueous-organic partitioning would be investigated in the first part of this
dissertation work, because of its relatively large MW, reduced accumulation was
expected based on literature data (Perkins et al., 1999). On the other hand, the
prophylactic oral dose of doxycycline is about 250 mg/week (MMWR, 1990). If 50% of
it is bioavailable after the first-pass effect, around 18 mg should be transferred through
skin in 24 h. Although the above TDD system could introduce the total amount required
in 24 h using appropriate patch dimensions (Perkins et al., 1999), much faster delivery
may be required for other drugs e.g., lidocaine hydrochloride (HCl). Iontophoresis as a
means of facilitation to achieve fast delivery is investigated here to increase the
accumulation using a novel conducting polymeric membrane as electrode.
As a conducting polymer, polyaniline (PANi) has attracted many researchers to
explore its unique properties and then apply it into different fields. In the area of
controlled release, its possibility to transform itself from almost an insulator to a high
conductor in different pH environments is the focus. In other words, it could be a very
good candidate membrane to carry out ion exchange, which matches the requirement of
the iontophoretic technique.
Due to its good environmental stability, easy synthesis, and special electrical and
mechanical properties, many researchers have concentrated on the permeability of PANi
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membrane for gases, water and small carboxylic acids (Wen et al., 1999); however, no
paper is available on iontophoretic TDD study, especially for large MW molecules such
as lidocaine HCl, doxycycline HCl.
In the iontophoretic TDD area, PANi could be used as an electrode to bind agent
ions illustrated in several patents (Parsi, 1988; Haak et al., 1990; Reynolds et al., 2002),
as a conductive membrane to split the donor chamber (Sanderson et al., 1988; Phipps,
1991, 1992), or only as an anode electrode (Untereker et al., 1992; Scott, 2001; Siman et
al., 2001; Fischer et al., 2004). However, none of them disclosed a doped PANi
membrane which functions simultaneously as both an anode and a control membrane for
the iontophoretic transdermal drug delivery system separating the donor reservoir from
the receptor.
Therefore, it would be a useful development if one can employ the conducting
polymer membrane film directly as an electrode in the iontophoretic technique, making it
both a controlled release membrane and an electron carrier. Such a system may eliminate
the unstable Ag part of traditional Ag|AgCl electrodes; at the same time a patch based on
such a new system is reusable instead of replacing Ag|AgCl electrode. Not only the
current density but also the membrane would control the release rate of drug: applying
different pore sizes of such films and adjusting the current, different sizes of molecules
from small (less than 200 D) to large (several thousand and larger) could go through,
which makes it possible to deliver several agents at different rates in one system. Lastly,
such a system is considerably cheaper than that of Ag|AgCl electrodes.
The objective in this second part of dissertation is first to synthesize the porous
PANi membrane and then employ it in a specific iontophoretic TDD system to study the
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permeation of different agents. Since it is a novel iontophoretic TDD using PANT
membrane as electrode, agents having different MW ranging from 200D to 500D in their
aqueous solutions would be primarily investigated. Next, aqueous-organic partitioning
between the reservoir and the liquid in the membrane pore would be tested. The regular
set of Ag|AgCl electrodes would also be used in conventional iontophoretic system to
compare the permeation results with this new electrode system.

1.5 Application with Porous Thermo-Sensitive Membrane
A further practical employment of the porous membrane-based aqueous-organic
partitioning system on TDD area is to combine certain thermo-sensitive polymers
into/onto the porous membrane system to form an "intelligent" TDD system. Fever, a
body condition where its core temperature becomes higher than normal, is the symptom
of many diseases (Vander et al., 1994) like malaria. When fever is detected, usually an
antibiotic such as doxycycline HCl should be taken immediately to prevent the worsening
of condition. The goal of this application is to coat a porous membrane or/and fill its
pores with a thermo-sensitive polymeric gel, which has a responsive range of
temperatures matching normal and fever temperatures of skin, then releases the antibiotic
i.e., doxycycline HCl, only under fever conditions.
Since 1940s many papers have investigated comb-like polymers with long sidechains which can crystallize independent of the main-chain (Mogri et al., 2000). Such
polymers may vary in their structures but have one common characteristic: they always
possess long alkyl groups extending from the main-chain. The specific property of these
polymers is that as their melting point is a critical structure transforming juncture, their
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permeability can be changed dramatically because of different morphology around this
temperature. That is: below the melting point of the side-chain crystals, the rigid but
brittle nature of those semi-crystalline materials becomes effective permeation obstacle
with the branch chain-based crystallinity; above such a point they appear softer like a
fluid and have much higher permeability owing to their amorphous structure. This unique
thermo-sensitive property has found polymers of this category applied to a wide range of
areas such as medical, agrochemical and industrial areas in which temperature-controlled
release is required. Examples of such applications are seed coating linking germination to
soil temperature, pesticide optimum-timing release related to the certain temperature, and
nitroglycerin transdermal release in a pulsatile way (Greene et al., 1993).
Among these "intelligent" polymers, poly-N-isopropylacrylamide (PNIPAAM)
has been intensely studied. In an aqueous solution it has a lower critical solution
temperature (LCST) of about 32°C (Yoshida et al., 1993; Vernon et al., 1996; Lin et al.,
2003), which is around to normal skin temperature (Bronaugh et al., 1991). Its linear or
branch form dissolves in water below the LCST and precipitates above it. If it is
crosslinked, it forms a temperature-responsive hydrogel, which swells below and deswells above the LCST. Such reversible thermo-sensitive polymer or its gels have been
applied in many biomedical fields: biosensing, immobilization of enzymes or bioactive
materials, controlled drug release, protein purification and affinity separation, etc.
In the case of a TDD system, regulation of the drug delivery is achieved by
turning "on" and "off" the rate controlling membrane in the transdermal device. This
membrane is fabricated from a thermo-sensitive polymer that undergoes a reversible
phase transition at a certain temperature (LCST). When the device is in contact with
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warm skin, the membrane is below its LCST and is "crystalline", therefore, impermeable.
However, with an ailing body, in most cases the skin temperature rises a little so that the
polymer membrane can be warmed above the LCST. Then it becomes amorphous and
very permeable to deliver the drug into the blood through skin steadily and continuously
until the disease is cured and the skin temperature is back to normal.
In order to make the LCST of PNIPAAM match the changes of physical
temperature, there are several ways of achieving chemical modifications for tailoring it
such as change of its hydrophilic/hydrophobic balance (Vernon et al., 1996), i.e., adding
extra hydrophilic comonomer like acrylic acid (AA) (Lin et al., 2003); change of the
block length of PNIPAAM (Mogri et al., 2001); adjustment of pH of polymer solution
(Luyten et al., 1999), etc.. Among those studied, AA comonomer has been investigated
most intensively and presented satisfactory results (Vernon et al., 1996; Lin et al., 2003).
To sum up, the relatively large molecule, doxycycline HCl is the basic model
drug to be tested for in vitro transdermal delivery based on the porous membrane based
aqueous-organic partitioning system. Several polymeric porous flat membranes, i.e.,
hydrophobic Celgard ® (polypropylene) and hydrophilic PVDF (polyvinylidene fluoride),
PANT film and PVDF coated with thermo-sensitive gel would be tested first to examine
whether the polymeric membrane would be a major obstacle for the agent to go through.
Then a skin membrane would be added beneath the polymeric one to test the
percutaneous diffusion performance. Since the present dissertation work was an initial
feasibility study for such a configuration, mouse skin was used in all in vitro experiments.

CHAPTER 2
EXPERIMENTAL PROCEDURES

2.1 Types of Experiments
Three types of membrane configurations were used in this dissertation: polymeric
membrane; skin membrane; a composite of polymeric and skin membranes. Four types of
in vitro membrane permeation experiments were implemented: polymeric membrane
alone, skin membrane alone, a composite of polymeric and skin membranes and such a
composite with enhancement.

2.1.1 In Vitro Delivery Based on Aqueous-Organic Partitioning System through a
Porous Polymeric Membrane Alone
This type of experiment was used to examine whether the porous polymeric membrane
would be a major obstacle for a relatively large and polar drug molecule (agent) i.e.,
doxycycline HCl (MW: 480.1) to go through with aqueous-organic partitioning taking
place along the diffusion path. Two types of polymeric membranes were tested:
hydrophobic and hydrophilic membranes using a couple of agent solutions having
different concentrations in the donor solutions prepared from a number of organic liquids
as solvents. As an extension of the study by Farrell and Sirkar (Farrell, 1996; Farrell et
al., 1997, 1999, 2001), a two reservoirs-based controlled release cell (Farrell, 1996) was
also used in this type of permeation tests along with the regular Franz diffusion cells. A
patch system using the same membranes was then tested employing the Franz cell.
In the controlled release application using a porous conductive membrane,
because of its novelty, a fundamental study of delivering agents of different MWs from
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their aqueous solutions was of primary focus.
2.1.2 In Vitro Delivery Based on Aqueous-Organic Partitioning System through
Skin Membrane Alone
The results from a porous membrane-alone type of permeation experiments facilitated the
selection of the polymeric membrane, concentration of agent solution and the solvent.
Franz cell was used for all permeation experiments with the skin membrane only. The
results from this type of experiment were used as control tests to compare the earlier
results from those using polymeric membrane alone and using a composite of polymeric
and skin membranes.
2.1.3 In Vitro Delivery Based on Aqueous-Organic Partitioning System through a
Composite of a Porous Polymeric and a Skin Membrane
The results from this type of experiments provided a perspective of TDD based on
aqueous-organic partitioning system through a composite of a porous polymeric and a
skin membrane: whether there was decent release from this system, whether the
accumulation was too low or even zero, and whether enhancements should be used to
facilitate agent transport for the next type of experiments.
As for the application with porous conductive membrane, agent in its aqueous
solution ended up being the primary focus.
2.1.4 Enhanced In Vitro Delivery Based on Aqueous-Organic Partitioning System
through a Composite of a Porous Polymeric and a Skin Membrane
Except for the application with a porous conductive membrane, chemical enhancements
were employed for the delivery of doxycycline HCl. Enhancers from three widely used
categories, amide, terpene and fatty acid (Smith et al., 1995), were tested to search for a
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specific compound which worked. Different enhancer concentrations were investigated.
As for the application with a porous conductive membrane, since iontophoresis
itself is a means of enhancing transport, no chemical enhancer was employed unless no
release was detected by iontophoresis. The first set of tests employed the agent in its
aqueous solution. Then TDD based on aqueous-organic partitioning system was tested.

2.2 Chemicals, Membranes (Polymeric and Skin Ones), Diffusion Cells and Patch
2.2.1 Chemicals

Doxycycline HCl (MW: 480.1), Sigma brand, was donated by Integrated
Pharmaceuticals, Boston, MA. Lidocaine HCl (MW: 270.8) was purchased from Aldrich,
Milwaukee, WI. Caffeine (MW: 194.2) and nicotine (MW: 162) were purchased from
Fisher Scientific, Fair Lawn, NJ.
Potassium phosphate monobasic anhydrous, acetic acid, atone, cineole and
linoleic acid were obtained from Sigma (St. Louis, MO). Light mineral oil, 1-octanol,
glycerol, ethanol, methanol (HPLC-grade) and acetonitrile (HPLC-grade) were purchased
from Fisher Scientific, Fair Lawn, NJ. Phosphate buffered saline (PBS) was supplied by
Fluka, Milwaukee, WI. Bio-PSA ® 7-4302 silicone adhesive was from Dow Corning
Corp., Midland, MI.
Silver wire (99.9%, 0.5mm), silver chloride (99.9%), hydrochloric acid solution
(1N) and NMP were purchased from Fisher Scientific (Fair Lawn, NJ).
Polyaniline (emeraldine base, MW ca. 65,000), N-isopropylacrylamide
(NIPAAM), acrylic acid (99%) (AA), N, N-methylene bisacrylamide (99%) (BIS), N, N,
N', N'-tetramethylene diamine (TEMED) and ammonium persulfate (APS) were
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purchased from Sigma-Aldrich, Milwaukee, WI.

2.2.2 Membranes
Celgard ® 2400 hydrophobic polypropylene flat films were from Celgard (Charlotte, NC).
Polyvinylidene fluoride (PVDF) Durapore ® hydrophilized films were purchased from
Millipore Corp. (Bedford, MA). The polymer PVDF is naturally hydrophobic; an
additional polymerized layer on the membrane surface and pores makes it hydrophilic.
Table 2.1 provides details of the polymeric membrane properties and dimensions.

Table 2.1 Characteristic Properties of Different Polymeric Membranes
Microporous Material
Pore size Porosity a Tortuosity Membrane
membrane (1-1m)
thickness (μm)
Celgard ®Polypropylene 0.035x0.2 0.38
5.0b
25
2400
film
PVDF film
Polyvinylidene 0.l
0.7
2.58'
100
fluoride
a Supplied
bPrasad

by manufacturer.

et al., 1988.

`Chen et al., 1999.

Polyaniline membrane was cast by evaporating polyaniline (emeraldine base)
(PANT) solution in NMP.
Thermo-sensitive gels, PNIPAAM and PNIPAAM-co-AA, were synthesized by
radical polymerization.
Skin membranes: Male hairless mice, strain SkH l, 8 weeks old, were supplied by
Charles River Laboratories (Wilmington, MA). Mice were euthanized by carbon dioxide
asphyxiation. Their skins were excised and kept at -30°C until used.
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2.2.3 Diffusion Cells
Two different diffusion cells were used. The first one consisted of two reservoirs-based
controlled release cell, each reservoir having a volume of about 0.9 ml and a diffusional
area of 2.53 cm 2 (shown in Figure 2.1) (Farrell, 1996). The other one was a standard
Franz diffusion cell (Permegear, Inc., Bethlehem, PA), with a diffusional area of 0.64
cm2 and a receptor compartment volume of 5.1 ml; for the patch system, the values of the
corresponding parameters were: 3.14 cm 2 and 9.5 ml.

Top piece

4 clearance ludo (or
!Jr & 32 term,
1.4

I

Bottom piece
O-ring groove to

4 threaded kale fir NV
11.32 Imo

Figure 2.1 The two reservoirs-based controlled released cell (Farrell, 1996).
2.2.4 Patch
Patches used were supplied by Hill Top Research, Inc., Cincinnati, OH. Figure 2.2 is a
schematic of the patch.
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Figure 2.2 Schematic of Hill Top ® patch.

2.3 Preparation of Agent Solutions
2.3.1 Agent in Organic Solvents
For doxycycline HCl as the agent, with 1-octanol as solvent, either 250 mg (Sol.1) or 500
mg (Sol.2) of the agent was transferred into 50 ml of 1-octanol. Then the solution was
stirred for 12 hours till it became clear for use. For light mineral oil as solvent, the agent
had a much lower solubility than that in 1-octanol. The amount added was 500 mg into
50 ml of light mineral oil so that there was enough agent present in a suspension. In
another case, the agent sample (500 mg) was suspended into 50 ml of 10% v/v ethanol in
light mineral oil and agitated over a magnetic stirrer for 12 hours. Fifteen minutes before
applying the agent solution into the donor part of the diffusion cells, certain amount (5,
10, 20% v/v) of enhancer (azone, cineole, or linoleic acid) was sometimes added into the
solution as a suspension and thoroughly mixed. For the 1-octanol-based systems, no
ethanol or enhancer was applied.
For caffeine as the agent, an amount of 200 mg of the agent was transferred into
20 ml 1-octanol. Then the suspension was stirred for 12 hours before use.
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For nicotine as the agent, an amount of 0.2 ml of the agent was transferred into 20
ml light mineral oil. Then the solution was stirred before use.

2.3.2 Agent in Aqueous Solution
Solutions of caffeine and doxycycline HCl in water were prepared by dissolving about
200 mg of each agent into 10 ml of water, while about 400 mg of lidocaine HCl was
dissolved into 10 ml of water. A solution of about 200 mg doxycycline HCl dissolved
into 10 ml of an ethanol-water mixture (EtOH:H 2O=2:1 v/v) with 5%v/v linoleic acid
was also prepared.

2.4 Preparation of Membranes
2.4.1 Preparation of Celgard ® and PVDF Membranes
A piece of Celgard® or PVDF film was cut into a circular shape having an area same as
that of the diffusion cells. The Celgard ® film was wetted by the following steps: the film
was dipped in 40% v/v ethanol/DI water solution for 4 hours, then was transferred to 20%
v/v ethanol/DI water solution overnight; after that the film was moved to 5% v/v
ethanol/DI water solution overnight; the last step was to soak it in DI water overnight.
Then these circular films were soaked into 10 % v/v ethanol/deionized water for 10
minutes; the water drops remaining on both surfaces were removed by rolling a glass rod
over the membrane. For the two reservoirs-based cells, the wetted membranes were
placed over each reservoir, and the cells were closed.
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2.4.2 Preparation of PANi Membrane and its Properties
For the preparation of a PANi film, an amount of 1.5 g of polyaniline was dissolved into
100 ml NMP and stirred for 1 hr (MacDiarmid et al., 1996). A regular gauze pad was
used to filter the resulting dark blue solution. The clear filtrate solution was then
transferred to a Rotavapor ® RE 111 (Flawil, Switzerland) to evaporate the solvent at
50°C (MacDiarmid et al., 1996) for about 70 minutes to yield about 20 ml of a sticky
solution. The PANi film was cast from such a solution on a glass plate. Doping such a
film was achieved by keeping the film in a solution of lN HCl for 24 hr (MacDiarmid et
al., 1996) then washing it by DI water and drying it.
The porosity of the membrane was obtained by measuring the weights of
membrane wetted with glycerol and dry membrane, converting the difference into the
void volume by taking the density of glycerol into account and then dividing by the dry
volume of the film. The Equation for the calculation of membrane porosity (C m) is:

(2.1)

where, W,,, and Wdry are the weights of wet and dry membrane, respectively.

ρglycero

(1.475 gm/ml) and V are the density of glycerol and the total volume of the membrane,
respectively.
The calculation of the value of the membrane parameter (ε m/τm) was carried out
by measuring the flux data from three diffusion experiments of caffeine with three
different concentrations as all other conditions were kept the same.
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2.4.3 Preparation of Thermo-Sensitive PVDF Membrane
Thermosensitive gels based on PNIPAAM and PNIPAAM-co-2%AA, were synthesized
by radical crosslinking copolymerization in aqueous solution: first an amount of 10 gms
NIPAAM, 0.5 mol% BIS, 1 mol% APS were transferred into 190 ml water with or
without 2 mol% AA. After bubbling with nitrogen for 10 minutes in a water/ice bath
(Huglin et al., 1997), 1 mol% TEMED was added into the solution along with 20 small
pieces of PVDF membranes. Then the system was left to polymerize in a water bath at
room temperature for 6 hr (Huglin et al., 1997). Before the diffusion experiments,
coated/soaked PVDF membranes were carefully pulled out from the gel solutions and the
gel attached on both surfaces of membrane were removed.
2.4.4 Preparation of Mouse Skin Membrane
The mice skins were first taken out from the freezer (-30°C) and put into a beaker filled
with room temperature water until they were defrosted. The mice skins from their dorsal
(back) sites were removed from the adhering fat deposits and then were cut into small
pieces of appropriate size and carefully mounted on top of the diffusion cells and left to
hydrate. After 1 hour of hydration, a drop of either 1-octanol or light mineral oil
(depending on which organic solvent was used) was applied on the surface of each piece
of mouse skin to wet it for 10 minutes if agent used was in organic solvent. Then each
piece of skin was covered carefully with the circular polymer membrane piece.

2.5 Experimental Setup
The donor part of the Franz diffusion cell was filled with 0.5 ml of the suspension (if
there was a suspension as in light mineral oil) containing agent solution, and the receptor
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compartment with isotonic phosphate buffer (pH 7.2) containing 0.1% v/v of 36%
aqueous formaldehyde as preservative (Sloan et al., 1991). Receptor solution temperature
was maintained at 37 ± 0.5°C and was constantly stirred at 600 rpm. The top of the donor
compartment was covered with triple layers of Paraflim ® . At predetermined times, 300 μl
samples were taken from the receptor compartment over a total period of either 24 or 120
h and were immediately replaced by the same volume of a fresh buffer solution. The
samples were kept frozen at 4°C prior to analysis by high performance liquid
chromatography (HPLC). The results are based on averages from 3 Franz cells.
The amount of the agent withdrawn with a sample was corrected in the
subsequent calculation of the cumulative amount penetrated. For the two-reservoirsbased-cell, after preparation of the flat membrane system, the device was submerged in a
volume of water chosen for analytical convenience, between 150 — 750 cm 3 . Samples
having a volume of 200 p1 were withdrawn periodically from the aqueous phase in the
glass vessel until agent concentration remained constant for three consecutive
measurements. The sample volume was negligible compared with the total aqueous
volume and the agent concentration in the surrounding water was extremely low relative
to its saturation concentration; therefore medium changes were not necessary. The mass
of agent released was calculated from the aqueous concentration and bath volume, and
plotted as a function of time to establish release profiles.
For the experiments using PANT membranes, they were cut to the shape fitting the
Franz diffusion cells. If delivery was facilitated by iontophoresis, such films were applied
in a large enough size to have its edge extruding out so that it could be connected to the
direct current (DC) power source as an anode (setup shown in Figure 2.3). The DC was
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generated by the stimulus isolator purchased from World Precision Instrument, Inc.,
Sarasota, FL. The details of the preparation of Ag|AgCl electrodes is available elsewhere
(Wang et al., 2003). All results are based on an average of the data from three Franz cells.

Power Supply

Figure 2.3 The iontophoretic setup using PANT film as a new electrode.

For the experiments using thermo-sensitive PVDF membranes, the water
temperature of the circulating bath was adjusted so that the surface temperatures of the
mouse skin would be either 32°C or 33°C, simulating the conditions of normal and fever
body temperatures, respectively.

2.6 Distribution Coefficient Study
A certain amount of agent was transferred to different volumes of deionized water,
respectively. Then the same volume of organic solvent e.g., 1-octanol or light mineral oil
was added into the same container. Each container was put on the stir plate and stirred for
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24 hours. The aqueous phase was centrifuged and its concentration of agent was analyzed
by high performance liquid chromatography (HPLC) as described later.

2.7 LCST Study of Thermo-Sensitive Gel
The measurements of the LCSTs of different thermo-sensitive gels were carried out in a
DSC Q100 (TA Instruments, New Castle, DE). Sample weights were around 25 mg.
Scanning temperatures were from 0°C to 50°C at a scanning rate of 5°C/min.

2.8 SEM Imaging
Membrane structure was characterized using a scanning electron microscope (SEM)
(LEO 1530 VP FE-SEM, Carl Zeiss, New York, US).

2.9 HPLC Calibrations for Model Drugs Used
2.9.1 Doxycycline HCl and Lidocaine HCl
Samples containing doxycycline HCl were analyzed by reverse phase high performance
liquid chromatography (HPLC), using a 4.6 x 150 mm Phenomenex Luna C18 5 μm
ODS column fitted to a Hewlett Packard 1090 automated isocratic system, with UV
detection at 346 nm (Perkins et al., 1999). The mobile phase consisted of 45:55 (v/v) of
acetonitrile and 0.02 M KH 2PO 4 in deionized water. The pH of this salt eluent was
adjusted to 3.0. Before use, the solution was degassed and filtered through Nalgene TM 0.2
μm nylon filter (Nalge Company, Rochester, NY). The injection volume was 40 μl and
the flow rate was set at 1.0 ml min -¹ . Under these conditions, a retention time of
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approximately 2 min was obtained for the agent. A calibration plot for doxycycline HCl
is shown in Figure 2.4. The equation of the regression line is: y=57871x-255488.

Concentration (µg/ml)

Figure 2.4 Calibration curve for doxycycline HC1.

For lidocaine HCl, HPLC analysis was performed using a Hewlett Packard 1100
LC with a reverse-phase

C18

column (Microsorb-MV TM , 15 cm, 5 gm, Agilent

Technologies) at a flow rate of 1 ml/min. Samples were detected at 220 nm using a
mobile phase having the composition of acetonitrile: 0.05 M monobasic potassium
phosphate (45:55 v/v, pH 3.0) and an injection volume of 40 A calibration plot for
lidocaine HCl is shown in Figure 2.5. The equation of the regression line is: y=56x+129.
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Concentration (μg/ml)

Figure 2.5 Calibration curve for lidocaine HCl.
2.9.2 Caffeine

For caffeine, HPLC analysis was performed using a Hewlett Packard 1100 LC with a
reverse-phase C¹8 column (Microsorb-MV TM , 15 cm, 5 μm, Agilent Technologies) at a
flow rate of 1 ml/min. It was detected at 270 nm using a mobile phase composition of
acetonitrile: methanol: water (10:20:70 v/v/v) and an injection volume of 20 111. A
calibration plot for caffeine is shown in Figure 2.6. The equation of the regression line is:
y=64x-86.
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Concentration (µg/ml)

Figure 2.6 Calibration curve for caffeine.
2.9.3 Nicotine

For nicotine, HPLC analysis was performed using a Hewlett Packard 1100 LC with a
reverse-phase C¹8 column (Microsorb-MV TM , 15 cm, 5 μm, Agilent Technologies) at a
flow rate of 1 ml/min. It was detected at 254 nm using a mobile phase composition of
methanol: water: acetic acid (45:55:1 v/v/v) and an injection volume of 50 [11. A
calibration plot for nicotine is shown in Figure 2.7. The equation of the regression line is:
y=11x+17.
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Concentration (14/ml)

Figure 2.7 Calibration curve for nicotine.

2.10 Calculations for Membrane Permeability, Agent Flux and its Accumulation
The permeation parameters of the agent were calculated by plotting the cumulative
corrected amounts (μg/cm²

²)

of the drug permeated through the membrane versus time

(hr). Calculation of the membrane penetration parameters was based on the assumption
that the amount of enhancer applied on the membrane is small, hence, there was minimal
effect on the solubility of the agent. The slope of the linear portion of the graph provided
average flux value (J) at steady state (μg/cm ²-hr).
Permeability (P, cm/hr) was calculated by:

(2.2)

AC receptor

(µg/ml): the difference of agent concentration in the receptor part in the given

time At (hr); Cdonor (µg/ml): agent concentration in the donor part; A: diffusional area
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(cm² ). For agent suspension for donor solution, it is the total concentration of both
soluble and insoluble agent.
Statistical analysis was performed using one-way analysis of variance (one way
ANOVA).

CHAPTER 3
RESULTS AND DISCUSSION

3.1 Experimental Results of In Vitro Delivery of Doxycycline HCl Based
on a Porous Membrane-Based Aqueous-Organic Partitioning System
3.1.1 Distribution Coefficient
The effective distribution coefficient K for doxycycline HCl between 1-octanol and water
was found to be 30, while that between light mineral oil and water was 0.13. Here K is
defined as

K=

Concentration of agent in organic phase
Total concentration of agent in aqueous phase

(3.1)

In water doxycycline HCl exists as the undissociated compound (boxy), the dissociated
doxycycline 11 ÷ (DoxyH+ ) plus dimers. The sum of these concentrations is the total agent
concentration used in the definition of K Equation (3.1). The agent concentration in
organic phase includes dissolved plus suspended amounts.

3.1.2 Release Profiles from Polymeric Membranes Using 1-Octanol and Light
Mineral Oil as Vehicles
Two different kinds of polymeric membranes were studied: hydrophobic Celgard

®

2400

and hydrophilic PVDF. All experiments used either 1-octanol or light mineral oil as the
solvent for the agent in either two reservoirs-based cell or Franz diffusion cell.

3.1.2.1 Release from Celgard ® 2400 Membrane in Two Reservoirs-Based Cell. For
the release from a 1-octanol-based reservoir system with Celgard ® 2400 membrane, in
the beginning, the change of concentration in the receiving reservoir was proportional to
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time (Figure 3.1). Thus it was a zero order release for this period (Guy et al., 1989;
Farrell et al., 1997); a straight line behavior was observed. Then a first order release was
observed with the characteristics of a quadratic curve (Figure 3.2) (Guy et al., 1989;
Farrell et al., 1997). It should be noted that zero order release can be continued for longer
lengths of time if the agent concentration in the receiver solution were much smaller (as
would be true in in vivo studies).

Time (day)

Figure 3.1 Controlled release of doxycycline HCl through Celgard ® 2400 membrane in
the two reservoirs-based controlled release cell for the first five days (reservoir solvent,
1-octanol. Sol.2).
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Time (day)

Figure 3.2 Controlled release of doxycycline HCl through Celgard ® 2400 membrane in

the two reservoirs-based controlled release cell for fourteen days (reservoir solvent, 1octanol. So1.2).
3.1.2.2 Release from PVDF Membrane. The hydrophilic PVDF membrane was tried

next to compare its release characteristics with those of Celgard ® 2400. For this
membrane, Franz diffusion cells were used. The results of release are presented in Figure
3.3. Table 3.1 illustrates the permeation data from different systems.
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Cell using PVDF (Sol. 1)

Patch using PVDF (Sol.1)

Cell using Celgard 2400 (Sol. 2) — Cell using PVDF (Sol. 2)

Time (hr)

Figure 3.3 In vitro release of doxycycline HCl using 1-octanol as vehicle through PVDF
or Celgard ® 2400 membrane over 24 hr.

Table 3.1 Permeation Data Using 1-Octanol as Vehicle for Different Diffusion Systems
Diffusion systems

Permeability
(cm/hr)

Flux
(μg/cm²-hr)

Q24a

(μg/cm²)
Two reservoirsbased cell system
0.002±0.0003
18±3
1150±300
using Celgard ®
2400 membrane
(Sol.2)
Franz diffusion cell
using Celgard ®
0.014±0.0006
139±6
2750±890
2400 membrane
(Sol.
2)
Franz diffusion cell
using PVDF
0.015±0.003
73±12
516±150
membrane (Sol. 1)
Franz diffusion cell
using PVDF
0.015E1002
150±22
2520±540
membrane (Sol. 2)
Hill Top ® patch
using PVDF
0.007±7.14E-05
36.0±0.4
395±3
membrane (Sol.1)
8

Q24, receptor concentration after 24 hr.
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Obviously, the PVDF membrane has a somewhat higher permeability and flux
than Celgard ® 2400. Theoretically, based on Fick's First Law, the formula of flux of the
permeating species can be expressed as (Kessler et al., 1992, 2001):

(3.2)

in which, K is the partition coefficient,

Deff

is the effective diffusion coefficient in the

membrane, AC is the concentration difference in the pore liquid of the two external
solution-pore liquid interfaces on two sides: Cm is the concentration in the pore liquid on
the donor side and CH? is that on the receptor side; 1 is the membrane thickness. The last
formula is utilized in the following calculation with C1R E.-- 0, effectively zero
concentration in the reservoir vessel having an aqueous phase; the donor chamber has the
organic phase.
The partition coefficient K of the agent between the reservoir organic solvent 1octanol and water is the same in the case of membranes, Celgard ® 2400 and PVDF. The
effective diffusion coefficient of the drug through water in the porous membrane may be
defined as (Prasad et al., 1988):
(3.3)

in which Em and τm are the porosity and tortuosity of the membrane, respectively, and
Dwater is the diffusion coefficient in free solution. For Celgard ® , Em=0.38 and τ m=5
whereas for PVDF, Em =0.7 and τm=2.58. Therefore (Deff/I) factor in Equation (3.2) is
essentially the same for both Celgard ® 2400 and PVDF films ((εm/τml):

0.38
5x25
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film).
There are two species of doxycycline drug in the aqueous phase, the undissociated
doxycycline (Doxy) and doxycycline (DoxyH + ). There are two unknowns here whose
values are needed before the total agent flux can be calculated. First, the relative
distribution between the two species has to be determined. Second, their diffusion
coefficients also need to be known. The first dissociation equilibrium constant K¹ for
doxycycline 1-1 -E is 10 -33 (Libinson, 1977):

(3.4)

The transport analysis is based on the following assumptions: (1) The agent
DoxyHCl is completely dissociated in water into DoxyH + and Cl. (2) DoxyH + is the
protonated form of the original base Doxy. (3) Dimerization of both DoxyH + and Doxy
are neglected due to the low value of the total agent concentration CT ~ 6.9)(10 4 M
(Bogardus et al., 1979).
Since the pores contained only an aqueous solution of DoxyH + , [Doxy] [W].
For a total agent concentration of Sol. 2 of 10 4 μg/ml, CT is

(3.5)

The following values were obtained by the solution of a quadratic equation
obtained from Equations (3.4) and (3.5): CDoxy= 157 μg/ml and CDox yH+=176 μg/ml. It was
assumed that their concentration in the receptor was zero. Hence, the total agent flux was:
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(3.6)

The diffusion coefficients of doxycycline in free solution

(DDoxy,water)

can be

obtained from the Wilke-Chang Equation (Wilke et al., 1955) and is equal to 3.93x10

-6

cm ²/sec. The diffusion coefficient of DpoxyH+ is to be obtained from considerations of
diffusion potential-based diffusion coefficient DDoxyH+Cl- obtained from the individual
values of DpoxyH+ and Da - and their charges (Newman, 1973):

(3.7)

DDox yfr for this calculation is assumed essentially equal to 3.93x10 -6 cm2/sec

corresponding to the undissociated DD oxy . Here z +=+1, z..=-1 and

Dr,_ = 2.03 x10-5cm² / sec (Newman, 1973), so that

Therefore for the Celgard ® 2400 film, the total flux of doxycycline HCl in both
forms from Equation (3.6) is:

Since the concentrations in the receptor part were always much less than the
donor part and the receptor side was well mixed,

CIR

was assumed to be 0 for all species

for flux calculation by Equation (3.6). (The value of J without consideration of ionization
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is 135.9 μg/cm²-hr.) Results of the theoretical flux values (J) obtained when values of all
the experimental parameters were introduced into Equation (3.6), are shown in Table 3.2.
This table also includes the corresponding experimentally observed values.
Table 3.2 Comparison of Calculated Flux Values and Experimental Ones
Membrane

Solution

Calculated value

Experimental value
μg/cm²-hr

Celgard® 2400
membrane
PVDF
membrane

Sol. 2
(2 reservoir-based
21.3
18±3
cell)
Sol. 2 (Franz cell)
191.9
139±6
Sol. 1 (Franz cell)
86.4
73±12
172.7
Sol. 2 (Franz cell)
150±22

Obviously, the flux results from the experimental data are quite close to those
calculated from the model equation. For the flux from the 2 reservoir-based cell,
however, with no stirring in the receptor part, the existing stagnant layer in such a system
has to be considered. As shown in Figure 2.l, two small donor cells immersed in a 200
ml reservoir may be considered in analogy to the diffusion from a droplet to a stagnant
fluid around it. From the volume of each cell (0.9 cm 3 ), the characteristic dimension of an
equivalent sphere is 1.2 cm. The Sherwood number (Sh) for this case is 2 (Welty et al.,
1976). Therefore, the mass transfer coefficients, kD oxy and kDoxyH+, are:

(3.8)

Introducing these values into the flux Equation (3.6), one obtains:

hr

-

μg/cm²
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(3.9)
which is close to the experimental value. It is to be noted that the permeabilities
calculated by Equation (2.2) utilized the total solute concentration in the organic solvent
in the reservoir. If the corresponding aqueous phase solubility is used as the value of
Cdonor, it will

be much lower for 1-octanol; therefore the value of permeability P will go

up. For light mineral oil considered later, it will go down since K for light mineral oil is
0.13. Note furthermore, that for the dispersion in light mineral oil,

Cdonor

included both

soluble and insoluble doxycycline HCl.
The results of transport for the patch system identified at the end of Table 3.1 will
be considered now. It is clear that all of the permeation parameters of the patch system
are lower than those from the Franz diffusion cell for the same PVDF membrane. It may
be justified by the fact that the patch system was more complex with a number of
uncertainties compared to the Franz cell with the membrane mounted. In the case of the
patch, the membrane was sealed to the agent reservoir by an adhesive; the extent of agent
absorption in the adhesive was unknown. Given other uncertainties such as bubbles
created during patch preparation (difficult to remove during experiments) and unexpected
leaks from the periphery of reservoir, it is not surprising that the release rate from the first
sample of patch was not as good as those from the Franz diffusion cell system.
To improve the permeability, the patch system was optimized: instead of filling
the agent suspension directly in the reservoir, it was transferred into a double layer of
cotton pad (originally housed in the reservoir of the patch obtained from the
manufacturer), then covered with a PVDF membrane. With the cotton pad holding the
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agent solution, the chances of peripheral leakage were considerably reduced, the creation
of bubbles was avoided, and the patch became a stable release source. For this revised
configuration, permeation results were close to those of its relevant membrane system as
shown in Table 3.3 and Figure 3.4.

Table 3.3 Permeation Data Using Light Mineral Oil as Vehicle from Different Diffusion
Systems
Permeability

Flux (μg/cm²-hr)

Q24 (μg/cm²)

Franz diffusion cell
using PVDF

0.03±0.006

146±27

1440±240

Hill Top ® patch
using PVDF

0.004±0.0008

22±4

267±22

0.025±0.003

133±16

885±250

Diffusion systems

(cm/hr)

membrane

membrane

Hill Top ® patch
using PVDF
membrane

and cotton pad

Figure 3.4 In vitro release of doxycycline HCl using light mineral oil as vehicle through
PVDF membrane over 24 hr.
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Since hydrophobic Celgard ® 2400 films needed several days of pretreatment to
get wetted for use, hydrophilic PVDF membrane was used in the following experiments.
The solvent, 1-octanol, has a strong odor; therefore, light mineral oil was employed to
test whether it would be a good replacement with light color and odorless property.
Figure 3.4 shows the controlled release profiles from the Franz cell system and the patchbased system; Table 3.3 gives the permeation data results from these setups.
On comparing these results with those based on l-octanol (Table 3.1), it is
observed that the permeation parameter is halved using 1-octanol; further the fluxes are
close to each other although much less solute was dissolved in the light mineral oil
(around 550 μg/ml) compared to that in 1-octanol. Applying light mineral oil as the
vehicle actually decreases the solubility of the agent strongly compared to 1-octanol; it
forms a suspension, which decreases the agent concentration in the solvent for
partitioning into water in the membrane pores. However, the distribution coefficients for
the agent between 1-octanol/water and mineral oil/water are 30 and 0.13, respectively. It
is the principal reason why in light mineral oil system, this antibiotic has a much higher
permeability. Therefore, the solvent choice was narrowed down to light mineral oil for
the experiments to be described next.
With these results, it is clear that a porous polymeric membrane in an aqueousorganic partitioning system should not be a major obstacle for the agent to pass through.
Therefore, in the next part, a mouse skin was used for test with the polymeric membrane
on top of it.
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3.2 Experimental Results of In Vitro Drug Delivery Based on a Porous MembraneBased Aqueous-Organic Partitioning System through Mouse Skin
3.2.1 Release Profiles of Doxycycline HCl from Porous Polymeric Membrane and
Mouse Skin Using 10% Ethanol in Light Mineral Oil as Vehicle in the Reservoir
First, two control experiments were made: controlled release through the mouse skin
without any polymeric membrane and through both polymeric membrane and mouse
skin. Since the agent is a polar drug having a relatively higher molecular weight, 10%
ethanol was used to enhance its transporting ability through skin. These release profiles
are shown in Figure 3.5, and the permeation parameters are given in Table 3.4.

-

Mouse skin without PVDF membrane

—
Mouse skin with PVDF membrane

Time (hr)

Figure 3.5 In vitro release of doxycycline HCl through mouse skin with and without
PVDF membrane over 24 hr.
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Table 3.4 Permeation Data* through Mouse Skin with and without PVDF Membrane

Diffusion systems

Permeability
(cm/hr)

Flux
(μg/cm²-hr)

Q²4

(μg/cm²

²
)

Hairless mouse
skin only without
0.001±0.0002
9.8±2.1
240±40
PVDF membrane
Hairless mouse
skin with PVDF 0 0 0
membrane
* Mineral oil in donor reservoir has 10% ethanol.

It is clear that a significant drug permeation rate was achieved through the skin;
however, apparently there was essentially no agent going through the skin after passing
through the aqueous pores of the PVDF membrane. The reason is likely to be as follows.
In the case of the bare skin, the light mineral oil based solution was directly in contact
with the skin. The light mineral oil-based swelling of the skin facilitated the drug
transport. However, when the water-filled pores of the PVDF membrane was imposed in
between, there was no such facilitation since the skin was no longer exposed to light
mineral oil. The stratum corneum of the skin is expected to be a difficult medium for
such a polar agent to go through unless facilitated by some means.
Next, three kinds of enhancers were investigated: azone (amide), cineole (terpene)
(Godwin et al., 1999; El-Kattan et al., 2000; El-Kattan et al., 2001), and linoleic acid
(fatty acid) in different percentage concentrations: 5%, 10%, 20% v/v. For the groups
including azone and cineole acid, respectively, very little of the agent accumulated in the
receptor, while the agent permeability and flux were close to zero. Only linoleic acid as
an enhancer yielded reasonable results as shown in Figure 3.6 and Table 3.5. A patch
system filled with 10% linoleic acid as enhancer was tried and yielded similar results in
the Franz diffusion cell system; these results are also included in this figure and table. In
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order to make the patch perform as well as the diffusion cell, the PVDF membrane was
mounted on the patch with epoxy two days before the diffusion experiment through the
mouse skin. In Table 3.5, data from a research group using human cadaver skin (Perkins
et al., 1999) are also listed for the purpose of comparison.
—40-5% Linoleic Acid as Enhancer
---01-10% Linoleic Acid as Enhancer
Patch with 10% Linoleic Acid as Enhancer

Time (hr)

Figure 3.6 In vitro release profile of doxycycline HCl with linoleic acid as enhancer
through PVDF membrane and mouse skin over 24 hr.
Table 3.5 Permeation Data through PVDF Membrane and Mouse Skin with Different
Amounts of Linoleic Acid and through a Human Cadaver Skin*
Diffusion systems
Permeability (cm/hr) Flux (μg/cm²- hr)
Q²4 (μg/cm² )
5% linoleic acid in
37±2
l.6±0.3
1.6E-04±3.2E-05
drug solution
10% linoleic acid in
63±9
2.7E-04±5.0E-05
2.7±0.5
drug solution
10% linoleic acid in
28±10
1.7±0.2
1.7E-04±1.5E-05
drug patch
Doxycycline HCl
across full-thickness
20*
human cadaver skin
4.8E-06±5E-07
0.13±0.01
from ethanol
vehicle*
* Perkins et al. (1999) have not given this data directly, and the number here was calculated from their

Figure 2 on the amount permeated versus time.
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Due to its long-chain double bond structure similar to lipid bilayer of skin,
linoleic acid is believed to disrupt the skin lipid packing and make them (lipids) more
dynamic (Chattaraj et al., 1995). This could explain why linoleic acid has significant
effect on the agent permeation in the current investigation.
Mouse skin was used in this experiment since this was an initial feasibility study.
It is known, however, that data from mouse skin provide higher permeability values than
would be observed in human cadaver skin (Roy et al., 1994; Ghosh et al., 2000; S agar et
al., 2001). Mouse skin in general is much thinner than human cadaver skin and also
possesses a different lipid composition within the stratum corneum. In view of the data
from a previously published cadaver skin experiment (Perkins et al., 1999), it is expected
that application of the membrane-skin system with aqueous-organic partitioning to a
human skin in vitro would result in a reasonable flux.
In addition to the 24-hour release, 120-hour long term release experiments have
also been carried out. The permeation data were similar to those from the 24-hour results
with steady releasing rate achieved. These results suggest that it is possible to transfer
this system to a transdermal patch later. Figure 3.7 shows the extended-time release
profile.
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1

—II—

5% Linoleic acid 10% Linoleic Acid]

Time (hr)

Figure 3.7 In vitro release profile of doxycycline HCl with linoleic acid as enhancer

through PVDF membrane and mouse skin over 120 hr.

3.2.2 Release Profiles of Caffeine and Nicotine from Porous Polymeric Membrane
and Mouse Skin Using 1-Octanol and Light Mineral Oil as Vehicle Respectively in
the Reservoir

To further test whether such a system works for other agents, two small polar drugs,
caffeine and nicotine of relatively smaller MWs (194.2 and 162), were also used. The
release profiles are shown in Figure 3.8 and Figure 3.9, respectively; their permeation
data are provided in Table 3.6. It is not surprising that, without any enhancer to facilitate
their transport, the permeation data for both agents were more than three times than those
from a similar system for doxycycline HC1.
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Figure 3.8 In vitro release profile of caffeine with 1-octanol as vehicle through PVDF
membrane and mouse skin over 24 hr.

Time (hr)

Figure 3.9 In vitro release profile of nicotine with light mineral oil as vehicle through
PVDF membrane and mouse skin over 24 hr.
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Table 3.6 Permeation Data of Small Polar Agents through PVDF Membrane and Mouse
Skin without Any Enhancer
Diffusion systems

Permeability

Flux

Q²4

(cm!hr) (μg/cm²-hr) (μg/cm²)
Caffeine
suspension in
0.09±0.01
892±62
4820±48
1-octanol
Nicotine solution
in light mineral oil
0.12±0.02
1180±189
17100±1520

3.3 Experimental Results of In Vitro Drug Delivery through Mouse Skin Using
Conductive Membrane as an Electrode
The results of characterization of PANi films needed for characterizing the membrane
transport of various agents through the PANi films are presented first. The permeation
study is focused initially on agents in their aqueous solution because it is a new
application of PANi in the area of iontophoretic TDD. Without this knowledge, the
behavior in aqueous-organic partitioning system cannot be explained. The release profiles
through PANi membrane of three solutes, e.g., caffeine, lidocaine HCl and doxycycline
HCl from their aqueous solutions are then illustrated. Next, the release rates are
determined from Fick's law of diffusion and compared with the data. The data obtained
when a mouse skin is added to the PANi film are analyzed subsequently. This has been
followed by iontophoretic study of the composite of PANi film and a mouse skin using
two different kinds of electrodes: one based on a conventional Ag|AgCl electrodes and
the other being based on PANi|AgCl. Finally, doxycycline HCl release based on an
aqueous-organic partitioning system is explored.
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3.3.1 Properties of PANi Membranes

The thickness of the PANi films was found to be 0.018 mm±0.002 mm. The porosity of
PANi films was found to be 0.67%±0.08% based on the measurements of three films.
The membrane porosity (C m) is quite low with potential contributions from some defects;
introduction of low levels of pore forming agents in the casting solution would have led
to higher porosity.
The value of the PANi membrane parameter (εm/τm ), where .c m is the membrane
tortuosity, was found to be 9E-4±7E-5 from an average of nine films by measuring fluxes
under different donor concentrations of caffeine solutions.
Combining Equations (3.2) and (3.3), the equation of flux (J) is changed to:
(3.10)

Therefore, the value of the membrane parameter (ε m/τm ) can be expressed as:
(3.11)

Next, three caffeine solutions of different concentrations were prepared: 5, 10,
20.4 mg/ml. From each solution in donor part, a flux value was obtained and used in
Equation (3.11) to calculate the membrane's (εm/τm); the averaged value, 9E-4, was used
in later calculations.
In addition to the thickness (1) as a known value, the diffusion coefficient of
caffeine in free solution
et al., 1955):

(Dcaf,water)

was obtained from the Wilke-Chang Equation (Wilke
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(3.12)

where M
—Water/ 11Water, VCaffeine, and T are the molecular weight, viscosity of water, molar
volume of caffeine, association factor of water (2.6) and temperature, respectively. The
molar volume is equal to 159.3, and the value of

DCaf,water

is 7.08x10 -6 cm2/s.

Table 3.7 lists this film's (ε m/τm) calculated from different flux levels for different
donor concentrations; the averaged value was used in the following calculations.
Table 3.7 The Value of PANi Membrane Parameter (6„/T„,) Calculated from Data of
Different Fluxes for Caffeine*
Concentration of

caffeine (mg/ml)
5
10

Flux

εm/τm

239.5

0.00083

Avg. (εm/τm)

(μg/cm²h)
0.00094
66.6
0.00096 9E-4±7E-5
136.2

20.4
* Using Equation (3.11).

3.3.2 Aqueous Solution System
3.3.2.1 Release Profiles from PANi Membranes. The results of the release of three
agents through PANi membrane as obtained in the Franz cell are presented in Table 3.8;
the results illustrate the permeation data for three different agents in terms of their
permeability, flux and 24-hr accumulation values. Obviously, doxycycline HCl, as the
agent having the largest MW among the three, had the least flux, permeability and
accumulation. Between caffeine and lidocaine HCl, although caffeine has a small MW, it
is believed that the higher concentration of lidocaine HCl in the donor solution (by a
factor of two) played a critical role in providing almost a doubled flux and six times
accumulation compared to those for caffeine. The following calculations provide a
justification for these results.
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Table 3.8 Permeation Data for Three Agents Released through PANT Membrane
Agent
Caffeine
Lidocaine HCl
Doxycycline HCl

Permeability
(cm/hr)
1.2E-2±9.0E-3
1.1E-2±3.5E-3
3.5E-3+7.0E-4

Flux
(μg/cm² hr)
240±177
461±147
72±14

Q²4

(μg/cm²)
570±250
3330±1760
307±100

Conventionally, the value of the flux of the permeating species may be obtained
by simple diffusion through the membrane pores (Kessler et al., 1992, 2001):

(3.13)

in which, D eff is the effective diffusion coefficient in the membrane, AC is the
concentration difference in the pore liquid of the two external solution-pore liquid
interfaces on two sides:
CIR

CH)

is the concentration in the pore liquid of the donor side and

is that in the receptor side; / is the membrane thickness. The last formula is utilized in

the following calculation with 0, effectively zero concentration in the receiver
vessel having an aqueous phase; for the donor chamber,

CID ::.4
-

C,

which is the agent

concentration in the donor solution. The partition coefficient K of the agent between the
reservoir liquid (aqueous solution) and pore liquid (aqueous solution) is assumed to be 1.
The effective diffusion coefficient of the agent through water in the porous
membrane may be defined as (Prasad et al., 1988)

(3.14)
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Wilke-Chang (Wilke et al., 1955) estimation method for diffusion coefficient in
free solution was used to calculate Dwater of different agents. Since the concentrations in
the receptor part were always much less than those in the donor part and the receptor side
was well mixed, Cm was assumed to be 0 for the following calculations. The implications
of ionization on the partitioning behavior considered earlier in Equations (3.4) to (3.6)
were also considered in such calculations. As for doxycycline HCl, since the donor
solution concentration was higher than 0.01 M, its dimerized form was included in the
calculation of its model flux value as well (Bogardus et al., 1979). Therefore, the value of
the flux in the model calculations has contributions from three components: flux of the
base (JDoxy ), flux of the protonated base

(JDoxyH+) and

flux of its dimer (Kh mer). As for

lidocaine HC1, however, such data for its dimerization are not available in literature,
therefore a general calculation was carried out in the manner shown in Equations (3.4) to
(3.6). Results of model flux predictions (J) obtained when all the experimental parameters
were introduced into Equation (3.13), are shown in Table 3.9. This table also includes the
corresponding experimentally observed values. Detailed calculations are provided after
Table 3.9.

Table 3.9 Comparison of Model Predictions and Experimental Flux Data for Three
Agents, Caffeine, Lidocaine HCl and Doxycycline HCl
Agent
Caffeine
Lidocaine HCl
Doxycycline HCl

Dwater-agent

(cm²/s)
7.08E-6
7.91E-6
6.59E-6

Model prediction
(μg/cm² hr)
260
573
198

Experimental flux
(μg/cm² hr)
240±180
461±150
72±14
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(1) Model flux of caffeine
Since caffeine is a neutral molecule which does not produce any charged ions in
solution, its flux is determined simply by using its concentration values in Equation
(3.13), where the donor solution concentration of caffeine is 20400 .tg/ml,

(3.15)

(2) Model flux of doxycycline HCl
How to calculate the model flux value of an ionizable salt agent has been
described earlier via Equations (3.4) to (3.6). Since the concentration of doxycycline HCl
was quite high (0.0425 M), the role of its dimerization has to be considered also in the
flux calculation (Bogardus et al., 1979), which was neglected earlier (Equation (3.6)).
There are four species of doxycycline agent in the aqueous phase; the formula
symbol of each and its concentration are indicated in separate brackets: the original base
doxycycline (Doxy) (CDoxy), doxycycline (DoxyH + )

(CDoxyH+),

doxycycline dimers

(DoxyH+)² (Cdi) or (Doxy) ²H+ (C di ) (Bogardus et al., 1979).
First, the total concentration CT of doxycycline in all forms was related to the total
concentration (C m ) of Doxy (CD oxy) and DoxyH + ( CDoxyH+ ) as the monomer form of
doxycycline by the equation from Bogardus et al. (Bogardus et al., 1979):
(3.16)
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where Kd is the dimerization constant and equal to 24 (Bogardus et al., 1979); here

CT = Cm + Cdi, = 20400ug /m/ = 0.0425mol / /

(3.17a)

where Cdi is the concentration of doxycycline dimers. Note that the dimerization equation
is (Bogardus et al., 1979):
(3.17b)

By solving Equation (3.16) for this value of CT,
(3.18)

(3.19)

From Equation (3.18), the concentration values of each monomer form of
doxycycline were obtained by the solution of a quadratic equation obtained from
Equation (3.4) (Libinson, 1977):

(3.4)

By solving Equation (3.4) together with Equation (3.18),
CDoxy = 3.01x 10 -3 M = 1445μg /m/ , and CDoxyH+ = 0.0181M = 8685 g /m/ .
u

Using Wilke-Chang estimation method (Wilke et al., 1955), the diffusion
coefficients of monomers and dimers of doxycycline HCl in free solution are (see Section
3.1.2.2 for DDoxyH+,water and the same method for that of dimers):
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(3.20)

The total flux of doxycycline HCl had three components: JDoxy ,

JDoxyH+

and Jdimer:
(3.21)

Therefore,
where

Without consideration of the existence of dimer forms of doxycycline HCl, the
predicted value of flux would be 232.0 μg/cm² h.
(3) Model flux of lidocaine HCl
Similarly, the flux of lidocaine HCl should have contributions from three sources.
However, the formation of its dimers under the high agent concentration in water of
0.1485 M is so far a hypothesis (Beronius, 2004); the following calculation is therefore
based on the general method shown in Section 3.1.2.2.
There are two species of lidocaine agent in the aqueous phase, the undissociated
lidocaine (Lido) and lidocaine H + (LidoH+ ). There are two unknowns here whose values
are needed before the total agent flux can be calculated. First, the relative distribution
between the two species has to be determined. Second, their diffusion coefficients also
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need to be known. The first dissociation equilibrium constant K 1 for lidocaine II+ is 10-7.2
(Sjoberg et al., 1996):
(3.22)

For a total agent concentration CT of lidocaine HC1,
(3.23)
The following values were obtained for the individual species by the solution of a
quadratic equation obtained from Equation (3.22): CLid o=26 µg/ml and CLidoH+=40194
μg/ml. It was assumed that their individual concentrations in the receptor were zero.
Therefore the total agent flux is:
(3.24)

The diffusion coefficients of lidocaine in free solution (DLido,water) can be obtained
from the Wilke-Chang Equation and is equal to 4.91x10 -6 cm²/sec. The diffusion
coefficient of DLidoH+ compound is obtained from considerations of diffusion potentialbased diffusion coefficient

DLidoH+CI-

obtained from the individual values of

DLidoH+

and

D a- and their charges:
(3.25)
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DLidoH+

for this calculation is assumed essentially equal to 4.91x10 -6 cm ² /sec

corresponding to the

undissociated

DLido.

Here

z_=-1

and

= 2.03 x10 -5 cm ² / sec (Newman, 1973), so that

Therefore, the total flux of lidocaine HCl in both forms from Equation (3.24) is:

If dimerization existed and its effect were included in the calculation, the model
flux would be lower as shown in the calculation for doxycycline HCl.
The flux results from the experimental data appear to be not far from those
calculated from the model equations especially for caffeine and lidocaine HCl. If
existence of dimerization of lidocaine HCl were considered, the model predictions would
probably have been closer to the experimental ones. The deviations are likely to be due to
the variations from film to film cut from different parts of a larger piece of film. From
these results, it is clear that such a slightly porous polymeric conducting membrane is
unlikely to be a major obstacle for these agents to pass through. Therefore, a mouse skin
was used next for tests with a PANi membrane on top of it.
3.3.2.2 Release Profiles from a Composite of PANi and Mouse Skin Membranes.

The results of the release of three agents through a composite consisting of a PANi
membrane with a mouse skin next to it are presented in Figure 3.10. Table 3.10 illustrates
the permeation data for each of the three agents. It appears that doxycycline HCl, the
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largest molecule, had apparently no release at all. Compared with the data of earlier
experiments in 3.2, it is not surprising; without an appropriate enhancer in the donor
solution, it is very difficult for doxycycline HCl to go through the mouse skin. For
caffeine and lidocaine HC1, the magnitude of the lidocaine HCl concentration (40 mg/ml,
higher than that of caffeine, 20mg/ml) is believed to have played a greater role here.
Iontophoresis was therefore employed next as an enhancement.
--o— Caffeine Lidocaine HCI

—Á—

Doxycycline HCI

Figure 3.10 Release profiles of three agents through a composite of PANi and mouse
skin membranes.
Table 3.10 Permeation Data of Three Agents Released through a Composite of PANi
and Mouse Skin Membranes

Agent
Caffeine
Lidocaine HCl

Doxycycline HCl

Permeability
(cm/hr)
2.9E-4±2.4E-5
5.0E-4±2.5E-5

0

Flux

Q²4

0

0

(μg/cm² hr)
(μg/cm²)
7.6±0.6 26±4
20.4±1.0
240±20
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3.3.2.3 Iontophoretic Release Profiles from PANi Membranes. For caffeine and
lidocaine HCl, the current density used was 0.2 mA/cm ² because of their relatively low
MWs; for doxycycline HC1, 0.3 mA/cm ² was chosen because its MW is 480.1. To study
the iontophoretic property of the PANi membranes, standard AgIAgCl electrode was
used. The results of the release of the three agents are presented in Table 3.11, which
illustrates the corresponding permeation data. As for caffeine, a neutral molecule, there
was an increase of about 30% in its flux (vis-a-vis Table 3.8), which has been mainly
brought about by electroosmosis (Pikal, 1992; Singh et al., 1994; Riviere et al., 1997).
For doxycycline HCl, there is over ten times increase in the flux (see Table 3.8), which
indicated potentially a promising release behavior if applied on top of a mouse skin. For
lidocaine HCl, however, there is a small decrease in the flux.
Table 3.11 Iontophoretic Permeation Data of Three Agents Released through PANi Film
Agent

Permeability
(cm/hr)

Caffeine

1.3E-2±3.4E-3

(i=0.2mA/cm ² )

Lidocaine HCl

1.0E-2±3.5E-3

Flux
(μg/cm² hr)

Q8*

(μg/cm²)

310±80

3290±2400

410±140

3080±1350

790±110

2760±4970

(i=0.2mA/cm²)

Doxycycline HCl
(i=0.3mA/cm² )

4.0E-2±5.6E-3

* 8 hours accumulation in the receptor part.

According to the Faraday's law, the iontophoretic flux of an ion can be expressed
as (Phipps et al., 1989; Banga, 1998)
(3.26)

in which, i, F, ti, and Zi are, respectively the applied current density, Faraday's constant,
the transport number of ionic species i and the electrochemical valence of the ion i under
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consideration. To simplify the calculation of t,, when the donor part contains only the
agent solution without any other ion, the major competing ion with the agent ion is Cl - ,
whose t°Cl- may be assumed to be 0.86 (Marro et al., 2001). The transport number for the
agent ion is then most likely to be 0.14. As for lidocaine HCl, similarly, its cation
transport number can be tentatively assumed to be 0.19 (Karami et al., 1997). For the
values of the current density applied, and the electrochemical valence for the charge ion,
the calculated flux results for lidocaine HCl and doxycycline HCl are shown in Table
3.12; they have also been compared with the experimentally observed values.
Table 3.12 Comparison of Model Predictions and Experimental Iontophoretic Flux Data

Current density

Valence

(mA/cm² )

Zi

ion

0.2

1

383

Doxycycline
II+ ion

410±140

0.3

1

752

790±110

Agent ion

Model
prediction
(μg/cm

²

hr)

Experimental
flux

(lig/cm ² hr)

Lidocaine H+

For both lidocaine HCl and doxycycline HCl, the experimental values are quite
close to the calculated values.
3.3.2.4 Iontophoretic Release Profiles from both PANi and Mouse Skin Membranes.

Three sets of iontophoretic experiments were carried out: in the first set, as a control test,
traditional AgIAgCl electrodes were used for the mouse skin only without the PANi
membrane. In the other two sets, with the PANi membrane and the mouse skin together,
either PANilAgCl configuration or the AgIAgCl configuration as electrodes was tested.
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Lidocaine HCl
The results of three sets of experiments are presented in Figure 3.11. Table 3.13
illustrates the permeation data for the different experimental configurations. The results
of the two different sets of electrodes were similar, which indicates that the conducting
PANi membrane could be a good replacement for the Ag electrode. And if its properties
such as porosity is increased (correspondingly tortuosity is likely to be reduced), it is
possible to enhance the flux and accumulation of drug release, i.e., another method of
control of transdermal drug delivery.

Time (hr)

Figure 3.11 Iontophoretic release profiles of lidocaine HCl through mouse skin with and
without a PANi membrane (i=0.2 mA/cm ²).
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Table 3.13 Iontophoretic Permeation Data of Lidocaine HCl Released through Mouse
Skin with and without a PANi Membrane (i=0.2 mA/cm ² )
Set

Permeability
(cm/hr)

Skin only
AgIAgCI electrodes
1.1E-2±2.6E-4
PANi+skin
AgIAgCl electrodes
1.0E-3±4.2E-4
PANi+skin
PANiIAgCl electrodes
1.0E-3±3.5E-4
* 10 hours accumulation in the receptor part.

Flux
(µg/cm² hr)

Q o*
(μg/cm²)

430±10

4160±140

48±20

348±78

43±15

392±130

Doxycycline HCl
It should be noted that for the sets of PANi membrane and mouse skin together, no
release was achieved in the absence of any enhancer added into the donor agent solution.
Therefore, instead of using a simple aqueous solution, 5% linoleic acid was added into
doxycycline HCl solution made of ethanol and water (EtOH: water=2:1, v/v). The reason
for using ethanol was to increase the solubility of linoleic acid into water.
The results of three sets of experiments are presented in Figure 3.12. Table 3.14
illustrates the permeation data for doxycycline HCl under different conditions.
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Skin only(control) — AglAgCl set —&—PANilAgCl set

Time (hr)

Figure 3.12 Iontophoretic release profiles of doxycycline HCl through mouse skin
with and without a PANi membrane (i=0.3 mA/cm ² ).
Table 3.14 Iontophoretic Permeation Data of Doxycycline HCl Released through Mouse
Skin with and without a PANi Membrane (i=0.3 mA/cm ² )
Set
Skin only
AgIAgCl electrodes
PANi+skin
AgIAgCl electrodes
PANi+skin
PANiIAgCl electrodes

Permeability
(cm/hr)

Flux
(μg/cm² hr)

(μg/cm²)

3.8E-3+6.7E-4

48.5±8.5

1020±640

0

0

0

5.6E-3+4.8E-3

94.4±81.2

Q²4

2760±3980

Unlike the performance of lidocaine HCl, there was no release of doxycycline
HCl from the AgIAgCl electrode set. By the end of the experiment of this set, a white gellike layer of AgCl was observed on the surface of the PANi film facing the Ag electrode
(Figure 3.13). Possibly such deposited matter blocked the pathway for doxycycline HCl
to go through the membrane first, and as such nothing came out through the skin.
Compared with the lidocaine HCl set, it is believed that with increased ethanol in agent
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solution as in the doxycycline HCl solution, increased amount of AgCl was dissolved
(Kratohvil et al., 1956; Anderson et al., 1967). However, as shown in the SEM picture of
Figure 3.13, such increased solubility of AgCl in the lidocaine case was much smaller in
the absence of alcohol; one observes instead individual particles on the PANi film facing
the Ag electrode (Figure 3.14). For the PANiIAgCl electrodes set, however, since Ag was
not used as electrode, no AgCl blocked the release (Figure 3.15) and the results are even
better than those of skin only set due to the enhancements of both iontophoresis and
linoleic acid. The high values of deviations could be from the non-homogeneous porous
structure of the mounted membranes, which is more important for larger molecules like
doxycycline HCl than smaller ones like lidocaine HC1.
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Figure 3.13 SEM picture of doped PANT film used in the AgIAgCl set for doxycycline
HCl diffusion.
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Figure 3.14 SEM picture of doped PANT film used in the AglAgCl set for lidocaine HCl
diffusion.
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Figure 3.15 SEM picture of doped PANi film used in the PANiIAgCl set for
doxycycline HCl diffusion.
3.3.3 Aqueous-Organic Partitioning System
For the permeation study of PANi membrane based on aqueous-organic partitioning
system, doxycycline HCl suspension in light mineral oil was used as the donor solution
so that its permeation results would be compared with those of PVDF membrane in a
general way. Figure 3.16 illustrates the release profile of doxycycline HCl through a
PANi membrane based on aqueous-organic partitioning system.
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Time (hr)
Figure 3.16 In vitro release of doxycycline HCl using light mineral oil as vehicle
through PANi membrane over 6 hr.
The permeability, flux and accumulation fog: six hours of this system were
0.0031±0.0018 cm/hr, 31±18 pg/cm ² hr and 80±46 μg/cm ² . Compared to permeation data
from aqueous solution in Table 3.8, Section 3.3.2, the permeabilities are close
(0.0035cm/hr from aqueous solution), while the flux (72 μg/cm² hr) is more than twice of
that from the partitioning system (31 μg/cm ² hr). Compared to permeation data from
PVDF system in Table 3.3, Section 3.1.2, all magnitudes obtained here are much smaller
(from PVDF system: P-0.03 cm/hr, J-146 μg/cm ² hr). It is believed that the rather small
porosity (for PANi, about 1%; for PVDF, 70%) is the primary reason for this low
delivery rate. Therefore it would be essential to increase the PANi membrane porosity to
further improve delivery from both aqueous solution system and aqueous-organic
partitioning system.
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3.4 Experimental Results of In Vitro Delivery of Doxycycline HCl Based on
an Aqueous-Organic Partitioning System through a Porous ThermoSensitive Membrane and a Mouse Skin

There were two types of porous thermo-sensitive membranes made:
PNIPAAM-immobilized (soaked/coated) thermo-sensitive PVDF membrane (PNIPAAM-PVDF) and
PNIPAAM-co-2mol%AA-immobilized (soaked/coated) thermo-sensitive PVDF
membrane (2%AA-PVDF). The LCSTs of such thermo-sensitive polymeric gels are
presented first. Then doxycycline HCl release profiles from those soaked/coated PVDF
membrane alone are illustrated. Permeation through a composite of thermo-sensitive
PVDF and mouse skin membranes are presented next. In addition, a relatively small
agent, namely, caffeine, was also tested using this thermo-sensitive membrane.

3.4.1 LCSTs of Thermo-Sensitive Polymeric Gels

The LCSTs of these two gels measured by DSC are about 32.6°C of PNIPAAM (32.633.8°C), about 33.0°C of PNIPAAM-co-2%AA (33.0-35.0°C). As described in the
introduction, such temperature ranges would match the change of skin temperatures
under normal and fever conditions: 32°C as regular one (Bronaugh et al., 1991), and to
simplify the different fever temperatures, 33°C is assumed to represent the skin
temperature under fever condition.

3.4.2 Release Profiles from Porous Thermo-Sensitive Membrane

Permeation experiments using doxycycline HCl suspension in light mineral oil as donor
solution were carried out at two different temperatures: 32°C mimicing normal skin
temperature and 33°C, skin temperature under fever condition.
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Figures 3.17 illustrates the polymer synthesis and the final structure. Figures 3.18
and 3.19 show the release profiles from PNIPAAM-PVDF and 2%AA-PVDF at 32°C
and 33°C, respectively. Their permeation data are illustrated in Table 3.15.

Figure 3.17 Schematic of PNIPAAM-co-AA synthesis.
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32°C —s— 33°C

Time (hr)

Figure 3.18 In vitro release of doxycycline HCl using light mineral oil as vehicle
through PNIPAAM-PVDF membrane at two temperatures over 1 hr.

Time (hr)
Figure 3.19 In vitro release of doxycycline HCl using light mineral oil as vehicle
through 2%AA-PVDF membrane at two temperatures over 1 hr.
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Table 3.15 Permeation Data of Doxycycline HCl Released through Different ThermoSensitive Membranes at Different Temperatures
Temp.
(°C)

32

PNIPAAM- PVDF
P
J
Q1*
(μg/cm ² h) (μg/cm ² )
(cm/hr)

P
(cm/hr)

2%AA -PVDF
J
Q1*
(μg/cm ² h)
(μg/cm ² )

0.14±0.06 1440±630 1210±590 0.11±0.09 1050±840 880±700

33
0.16±0.03 1560±280
* Q,: receptor concentration after 1 hr.

1770±510 0.19±0.06 1900±570

1390±380

It is obvious that at a higher temperature of 33°C, which is in the range of their
phase changing temperatures (LCSTs), both thermo-sensitive PVDF membranes yielded
higher permeability, flux and accumulation than those from 32°C, which is below their
LCSTs. Figures 3.19 and 3.20 clearly show that the thermo-sensitive gel, either
PNIPAAM or PNIPAAM-co-2mol%AA, was both partially coated on the surface of
PVDF membrane and penetrated into PVDF membrane pores during synthesis. As
described in Chapter 1, it is believed that at a temperature lower than the LCST, e.g.,
32°C, the polymer chains are expanded and occupy membrane pores, which partially
block the transportation path of doxycycline HCl; when, however, the temperature is
raised to 33°C, the polymer underwent a phase change; the chains shrank and condensed
to a certain degree (Figure 3.21) (Park et al., 1998), which partially opened the membrane
pores so that the system could have an increased permeability, flux and accumulation.
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a. Surface image of PVDF membrane without modification

b. Surface image of PNIPAAM PVDF membrane
-

0. Surface image of 2%AA-PVDF membrane

Figure 3.20 SEM images of PVDF membrane surfaces with and without modification by

thermo-sensitive gels.
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Cross section image of PVDF membrane without modification

Cross section image of PNIPAAM-PVDF membrane c. Cross section image of 2%AA-PVDF membrane

Figure 3.21 SEM images of PVDF membrane cross section with and without
modification by thermo-sensitive gels.
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Figure 3.22 Thermo-sensitive permeation of doxycycline HCl through polymeric gelimmobilized PVDF membrane (Adapted from Park et al., 1998).
From Table 3.15, permeation results from 2%AA-PVDF membrane indicated a
much stronger effect of temperature than those from PNIPAAM-PVDF. Therefore,
2%AA-PVDF membrane was selected for study on top of a mouse skin for in vitro
delivery of doxycycline HCl through a composite of the two membranes.

3.4.3 Release Profiles from a Composite of Porous Thermo-Sensitive PVDF and
Mouse Skin Membranes
Table 3.16 shows the permeation data of doxycycline HCl release through a composite of
2%AA-PVDF and mouse skin membranes as well as the data from a simple aqueousorganic partitioning system using the same donor solution, enhancer (linoleic acid),
PVDF and skin membranes for comparison (Table 3.5, Section 3.2.1).
Table 3.16 Permeation Data of DoxyHCl through 2%AA-PVDF and Mouse Skin
Membranes*
J
Temperature
P
(μg/cm² h)
(°C)
(cm/hr)
2%AA-PVDF
0
0
32
+ mouse skin
2.6±0.3
2.6E-4 ±3E-5
33
Regular PVDF
25
+ mouse skin
2.7±0.5
2.7E-4±5e-5
(room temp.)
* At the 47 th hr, DoxyHCl release was detected in the receptor for the 32°C system.
Configuration

Q²4

(μg/cm²²)
0
30±6
63±9
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As shown in the Table 3.16, at normal skin temperature, 32°C, there is no release
of doxycycline HCl from this system for the first 24 hr; while at 33°C, which represents
fever condition, the release data were very close to those from regular PVDF system
except the 24 hr accumulation; the deviation in the latter is believed to be due to the
following reason: the immobilized thermo-sensitive gel on/into the PVDF membrane
increased the lag time of the agent penetration so that it had less time for more agent to
go through. However, it did achieve the so called "on-off" switch function as an
intelligent polymeric TDD system. It is to be noted that for the release case at 32°C,
starting at the 4.7 th hr, a small amount of DoxyHCl was also detected from the receptor.
In addition to the permeation of the relatively large molecular weight agent, such
as, doxycycline HC1, a smaller agent, namely, caffeine was also studied using such a
thermo-sensitive system at two different temperatures. From Figure 3.22, one observes
relatively little difference between the two termperatures. Because of the relatively small
size of caffeine molecules, one should not expect much difference in the permeation
results from two temperatures, i.e., although the membrane pores are partially blocked, it
did not impose much resistance to the small molecules (unlike that in the case of 32°C for
doxycycline HCl) and only resulted in a smaller porosity. It is possible that with more
time, one could achieve the same level of 24-hour accumulation achieved through a
regular PVDF membrane and mouse skin.
Figure 3.23 shows the release profiles of caffeine at two different temperatures,
and Table 3.17 illustrated their permeation data as well as the data of release through a
regular PVDF membrane and mouse skin for comparison.
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Figure 3.23 In vitro release of caffeine using 1-octanol as vehicle through 2%AA-PVDF
membrane at two temperatures over 24 hr.

Table 3.17 Permeation Data of Caffeine through 2%AA-PVDF and Mouse Skin
Membranes
Configuration
2%AA-PVDF
+ mouse skin
Regular PVDF
+ mouse skin

Temperature
(°C)
32
33
25
(room temp.)

P
(cm/hr)
0.03±0.001
0.03±0.002

J
(μg/cm² h)
303±12
315±19

0.09±0.006

892±62

Q²4

(μg/cm²)
4120±120
4120±530
4820±50

The release profiles and permeation data matched the expectation: at 24 th hr the
thermo-sensitive system did not stop release as the straight line still extended while as
Figure 3.8 showed the regular PVDF membrane system almost reached the "plateau"
period. There is not much difference in release profiles between 32°C and 33°C: the
release lines almost overlapped with each other, and the permeation results of 33°C were
just slightly higher than those of 32°C.
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Based on the results of two agents: doxycycline HCl (MW: 480) and caffeine
(MW: 194), it is clearly indicated that PNIPAAM- and PNIPAAM-co-2mol%AA gel
based thermo-sensitive PVDF membrane would function well for relatively large size of
agent molecules such as doxycycline HCl; while for small size of agent molecules such
as caffeine, other thermo-sensitive polymeric gels might be needed to make PVDF
membrane more "dense" at 32°C to minimize the release, or employ certain membranes
of small porosity immobilized by PNIPAAM gel to achieve the same goal.

CHAPTER 4
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE STUDIES

4.1 In Vitro Drug Delivery Based on an Aqueous-Organic Partitioning System
through a Composite of Porous Polymeric and Skin Membranes
The controlled release of a polar antibiotic drug of larger molecular weight i.e.,
doxycycline HCl using aqueous-organic solute partitioning and microporous
polymeric/mouse skin membranes has been studied. The reservoir had either the agent
solution in 1-octanol or a dispersion/solution of the agent in light mineral oil.
Hydrophobic porous PP Celgard ® membrane and hydrophilized porous PVDF
membranes containing water in the pores were investigated. The transport rates of the
agent through such membranes in aqueous-organic partition systems were accurately
predicted using appropriate organic-aqueous partition coefficients. After a variety of
tests, the porous PVDF membrane and light mineral oil were selected for in vitro test.
Satisfactory release profiles were achieved not only from the in vitro membrane test but
also from in vitro patch test after its optimization. These demonstrate the practical
potential of aqueous-organic partitioning systems and porous membranes to achieve
useful controlled release rates. Long term release experiments spanning 120 hours were
also carried out and the results were satisfactory. The enhancer linoleic acid was essential
to successful release in experiments using the mouse skin.
Agents of smaller molecular weights such as nicotine and caffeine were
investigated employing aqueous-organic partitioning and microporous polymeric and
mouse skin membranes as well. Without applying any enhancer such as ethanol or
linoleic acid needed for the delivery of doxycycline HCl, the transport rates of these
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smaller molecules through a mouse skin were quite high: for nicotine (MW: 162), the
permeability, flux and 24 hr accumulation were 0.12±0.02 cm/hr, 1180±189 μg/cm ² -hr
and 17100±1520 μg/cm² , respectively; for caffeine (MW: 194): 0.09±0.01 cm/hr,
892±62 μg/cm² -hr and 4820±48 μg/cm², respectively.
Based on the release profiles obtained for these three agents of different molecular
weights employing aqueous-organic partitioning and microporous polymeric membrane,
satisfactory transdermal drug delivery results were achieved.

4.2 In Vitro Iontophoretic Drug Delivery through a Conductive
Membrane as an Electrode Placed on a Mouse Skin
Iontophoretic TDD has been studied using porous membranes of polyaniline, a
conducting polymer. Three agents of different molecular weights, caffeine (MW: 194),
lidocaine HCl (MW: 271) and doxycycline HCl (MW: 480), were model agents for the
tests. Because it is a novel application of PANT membrane in iontophoretic TDD field, the
permeation investigation focused first on agents in their aqueous solution. The transport
rate of each agent through such a conducting membrane was accurately predicted using
simplified mass transport models. Satisfactory release profiles were achieved not only
from the in vitro membrane test but also from in vitro iontophoretic TDD system with a
mouse skin. Iontophoresis using PANi|AgCl electrodes presented satisfactory release
results. In addition, iontophoretic TDD experiments were performed using both Ag|AgCl
electrodes and PANi|AgCl electrodes for comparison. For doxycycline HCl, the flux and
24-hour accumulation from the PANi|AgCl set were 94.4±81.2 μg/cm²-hr and
2760±3980 μg/cm² , respectively; those from the Ag|AgCl set were zero. For lidocaine
HCl, the flux and 10-hour accumulation from the PANi|AgCl set were, respectively
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43±15 μg/cm² -hr and 392±130 μg/cm²; ; the corresponding values from the Ag|AgCl set
were 48±20 μg/cm²-hr and 348±78 μg/cm². Porous polyaniline membrane appears
capable of replacing the Ag part of Ag|AgCl electrode systems; further it can exercise
additional control over agent transport rate. As a new material for iontophoretic TDD
system, there are many other aspects worthy of additional investigations.
Aqueous-organic partitioning system using the PANi membrane was also studied.
However due to the rather low porosity of PANi membrane, the permeation rates were
much lower than those from its aqueous solution counterpart; this suggested that future
work should focus on making more porous PANi membranes.

4.3 In Vitro Drug Delivery through a Porous Thermo-Sensitive
Membrane Placed on a Mouse Skin
The thermo-sensitive membrane, a type of intelligent biomaterial, was synthesized by
immobilizing the thermo-sensitive polymeric gel, PNIPAAM or PNIPAAM-co2mol%AA both on the surface and inside the pores of PVDF membrane. Such a modified
membrane has different permeation properties at different temperatures based on the
phase changes around its LCST. At 33°C, which simulates the skin temperature under
fever condition, the permeability and flux of 2%AA-PVDF coating (0.19±0.06 cm!hr and
1900±570 μg/cm²-hr, respectively) were almost double of those at 32°C (0.11±0.09
cm/hr and 1050±836 μg/cm²-hr, respectively) for the agent doxycycline HCl. Both SEM
surface and cross section images of modified PVDF membrane clearly illustrated that
there was a thin layer of thermo-sensitive gel coated on the surface, and membrane pores
were partially filled with the gel as well, which explains the different permeation rates at
different temperatures. Further in vitro study with a mouse skin mounted beneath the
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thermo-sensitive PVDF membrane demonstrated its release-"on/off' switch function: at
32°C representing normal skin temperature, there was no doxycycline HCl release
through skin, while at 33°C, the ailing condition, 30 μg/cm²² of doxycycline HCl was
accumulated in the receptor through the skin after 24 hours with the permeability and flux
data being very close to those from the composite of regular PVDF and skin membranes.
However, for smaller molecules such as caffeine, different temperatures indicated almost
the same permeation profiles.
This part of research simplified and assumed that the normal skin temperature is
32°C, and that under fever conditions is 33°C. In fact, variations of both body and skin
temperatures are more complicated. Skin temperatures of different body parts, adults and
children vary (Masters, 1980; Suleman et al., 2002). When fever occurs, with less
circulation in the capillaries of skin tissue, the skin temperature could even go lower than
normal (Silberstein, 1997). Therefore, many other aspects have to be considered in future
to make such a thermo-sensitive TDD system more pragmatic and feasible.

4.4 Recommendations for Future Studies
Successful prediction of the flux values of membrane alone permeation experiments for
aqueous-organic partitioning TDD system, and agents in their aqueous solution for
iontophoretic TDD system has been achieved based on ion transport, Fick's First Law
and the principle of electroneutrality. It would be more meaningful if one can build a
mathematical model for the TDD system of a composite of porous polymeric and skin
membranes, which would facilitate the selections of both membranes and agents for the
optimized formulation and design of transdermal patches.
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Synthesis of a PANi membrane with a higher porosity would be another
challenge. A more porous PANi membrane would yield higher release rate from the
aqueous-organic partitioning system. Different porosity would allow this new
iontophoretic TDD system control the release rate by both current density and
membrane's own property: big dosage of certain drugs could be fulfilled by either higher
porosity or higher current density or both and vice versa. In the case of the model
prediction (Equation (3.26)), it is clear that properties such as porosity, thickness of
membrane used were not involved. It would be another challenge to find out whether
those properties would not have an impact on the release profile or were overruled by
iontophoresis.
The intelligent TDD system as a thermo-sensitive one reported here is another
promising area in the pharmaceutical industry. The PVDF membrane immobilized with
the thermo-sensitive PNIPAAM-co-2mol%AA gel worked well for the delivery of
doxycycline HCl, a relatively large molecular weight agent; however, for a smaller agent,
one still needs to find either another membrane with either smaller pore size or porosity
or another thermo-sensitive material to modify it. Therefore, selections of membrane and
thermo-sensitive polymers play a great role in successfully delivering different agents. As
mentioned above, temperature control is another bigger challenge for this system. Is it
possible to customize such a thermo-sensitive transdermal patch based on different sexes,
ages, races and different targeting time, sites? It would be great interest to further this
aspect of the dissertation work in the future.

APPENDIX

STRUCTURE OF DOXYCYCLINE HCL

The chemical structure of doxycycline HCl is illustrated below.

REFERENCES

Anderson, K. P., Butler, E. A., Anderson, D. R. & Woolley, E. M. (1967). The solubility
of silver chloride and the concentration of silver-containing species in ethanolwater mixtures. Journal of Physical Chemistry, 71, 3566-3569.
Banga, A. K. (1998). Electrically Assisted Transdermal and Topical Drug Delievery: 172.
London, UK: Taylor & Francis Ltd.
Beronius, P., Dr.; Personal Communication. Sept 13, 2004.
Bogardus, J. B., Blackwood, R. K., Jr. (1979). Solubility of doxycycline in aqueous
solution. Journal of Pharmaceutical Science, 68, 188-194.
Borodkin, S., Tucker, F. E. (1975). Linear drug release from laminated hydroxypropyl
cellulose-polyvinyl acetate films. Journal of Pharmaceutical Science, 64, 12891294.
Bos, J. D., Meinardi, M. (2000). The 500 Dalton rule for the skin penetration of chemical
compounds and drugs. Experimental Dermatology, 9, 165-169.
Bronaugh, R. L., Collier, S. W. (1991). Chapter 19: Protocol for In Vitro Percutaneous
Absorption Studies. Bronaugh, R. L., Maibach, H., Ed. In Vitro Percutaneous
Absorption: Principles, Fundamentals, and Applications: 237-241. Boca Raton:
CRC Press, Inc.
Burnette, R. R. (1989). Iontophoresis. Hadgraft, J., Guy, R. H., Ed. Transdermal Drug
Delivery: Developmental Issues and Research Initiatives. New York City: Marcel
Dekker, Inc.
Chattaraj, S., Walker, R. (1995). Chapter 1.2. Smith, E. W., Maibach, H. I., Ed.
Percutaneous Penetration Enhancers: 5-15. Boca Raton, FL: CRC press.
Chen, H., Kovvali, A. S., Majumdar, S. & Sirkar, K. K. (1999). Selective CO² separation
from CO2-N2² mixtures by immobilized carbonate-glycerol membranes. Industrial
and Engineering Chemistry Research, 38, 3489-3498.
Chien, Y.W. (1982). Novel Drug Delivery Systems: Fundamentals, Developmental
Concepts, and Biomedical Assessments. Chapter 2. New York: Marcel Dekker.
Chong, S., Fung, H-L. (1989). Transdermal drug delivery systems: pharmacokinetics,
clinical efficiency, and tolerance development. Hadgraft, J., Guy, R. H., Ed.
Transdermal Drug Delivery: Developmental Issues and Research Initiatives: 135.
New York City:, Marcel Dekker.

88

89

El-Kattan, A. F., Asbill, C. S., Kim, N. & Michniak, B. B. (2001). The effects of terpene
enhancers on the percutaneous permeation of drugs with different lipophilicities.
International Journal of Pharmaceutics, 215, 229-240.
El-Kattan, A. F., Asbill, C. S. & Michniak, B. B. (2000). The effect of terpene enhancer
lipophilicity on the percutaneous permeation of hydrocortisone formulated in
HPMC gel systems. International Journal of Pharmaceutics, 198, 179-189.
Farrell, S. 1996. A Controlled Release Technique Using Microporous Membranes. Ph.D.
Dissertation: 192. New Jersey Institute of Technology. Newark, NJ.
Farrell, S., Sirkar, K. K. (1997). A reservoir-type controlled release device using
aqueous-organic partitioning and a porous membrane. Journal of Membrane
Science, 130, 265-274.
Farrell, S., Sirkar, K. K. (1999). A mathematical model of an aqueous-organic partitionbased controlled release system using microporous membranes. Journal of
Controlled Release, 61, 345-360.
Farrell, S., Sirkar, K. K. (2001). Mathematical model of a hybrid dispersed networkmembrane-based controlled release system. Journal of Controlled Release, 70, 5161.
Fischer, W., Haas, R. & Zimmermann, C. 2004. Transdermal delivery system (TDS) with
electrode network. U.S. Patent Application Pub. No.: 2004/0193089 Al
Flynn, G., Smith, R. (1972). Membrane diffusion III: influence of solvent composition
and permeant solubility on membrane transport. Journal of Pharmaceutical
Science, 61, 61-66.
Ghosh, B., Reddy, L. H., Kulkarni, R. V. & Khanam, J. (2000). Comparison of skin
permeability of drugs in mice and human cadaver skin. Indian Journal of
Experimental Biology, 38, 42-45.
Godwin, D. A., Michniak, B. (1999). Influence of drug lipophilicity on terpenes as
transdermal penetration enhancers. Drug Development and Industrial Pharmacy,
25, 905-915.
Greene, L., Phan, L.X., Schmitt, E.E. & Mohr, J.M. (1993). Side-chain crystallizable
polymers for temperature-activated controlled release. El-Nokaly, M.A., Pratt,
D.M. & Charpentier, B.A., Ed. Polymeric Delivery Systems: Properties and
Applications. Washington, DC: American Chemical Society.
Grimnes, S. (1984). Pathways of ionic flow through human skin in vivo. Acta Derm
Venereol, 64, 93-98.

90

Guy, R., Hadgraft, J. (1989). Chapter 3: Selection of Drug Candidates for Transdermal
Drug Delivery. Hadgraft, J., Guy, R. H., Ed. Transdermal Drug Delivery:
Developmental Issues and Research Initiatives: 59-82. New York: Marcel
Dekker.
Haak, R. P., Theeuwes, F. & Gyory, J. R. 1990. Electrotransport transdermal system.
U.S. Patent: 4,927,408
Helmstadter, A. (2001). The history of electrically-assisted transdermal drug delivery
("iontophoresis"). Pharmazie, 56, 583-587.
Huglin, M. B., Liu, Y. & Velada, J. L. (1997). Thermoreversible swelling behaviour of
hydrogels based on N-isopropylacrylamide with acidic comonomers. Polymer, 38,
5785-5791.
Kalia, Y. N., Naik, A., Garrison, J. & Guy, R. H. (2004). Iontophoretic drug delivery.
Advanced Drug Delivery Review, 56, 619-658.
Kanikkannan, N. (2002). Iontophoresis-based transdermal delivery systems. BioDrugs,
16 339-347.
Karami, K., SjÖberg, H. & Beronius, P. (1997). Ionization conditions for iontophoretic
drug delivery. Electrical conductance and aggregation of lidocaine hydrochloride
in 1-octanol at 25°C. International Journal of Pharmaceutics, 154, 79-87.
Kessler, S. B., Klein, E. (1992, 2001). Part IV. Dialysis Chapter 11: Definations. Ho, W.
S., Sirkar, K. K., Ed. Membrane Handbook. Boston: Kluwer Academic.
Kratohvil, J., Tezak, B. (1956). The influence of the composition and the properties of the
solvent on complex formation between silver and chloride, bromide, iodide, and
thiocyanate ions. Recueil des Travaux Chimiques des Pays-Bas et de la Belgique,
75 774-780.
Kydonieus, A. F., Ed. (1980). Controlled Release Technologies: Methods, Theory and
Applications. Boca Raton: CRC Press.
Langer, R. (1990). New methods of drug delivery. Science, 249, 1527-1533.
Libinson, G. S. (1977). Doxycycline. Potentiometric titration. Antibiotiki, 22, 10931095.
Lin, P., Zheng, H., Zhang, C., Yang, H., Li, D. & Xu, J. (2003). Preparation of
temperature-sensitive polymer with regulated phase transition temperature and its
application in the fluoroimmunoassay. Chinese Journal of Analytical Chemistry,
1 1-4.

91

Luyten, M.C., Ekenstein, G.O.R.A. van & Brinke, G. ten (1999). Crystallization and
cocrystallization in supramolecular comb copolymer-like systems: blends of
poly(4-vinylprridine) and pentadecylphenol. Macromolecules, 32, 4404-4410.
MacDiarmid, A. G., Scherr, E. & Tang, X. 1996. High molecular weight polyaniline
films. U.S. Patent: 5,484,884
Marro, D., Kalia, Y. N., Delgado-Charro, M. B. & Guy, R. H. (2001). Optimizing
iontophoretic drug delivery: identification and distribution of the charge-carrying
species. Pharmaceutical Research, 18, 1709-1713.
Masters, J. E. (1980). Comparison of axillary, oral, and forehead temperature. Archives
of Disease in Childhood, 55, 896-898.
MMWR (1990). Recommendations for the prevention of malaria among travelers.
MMWR Recomm Rep, 39, 1-10.
Mogri, Z., Paul, D. R. (2000). Membrane formation techniques for gas permeation
measurements for side-chain crystalline polymers. Journal of Membrane Science,
175 253-265.
Mogri, Z., Paul, D. R. (2001). Gas sorption and transport in poly(alkyl (meth)acrylate)s.
I. permeation properties. Polymer, 42, 7765-7780.
Newman, J. S. (1973). Electrochemical Systems. Table 75-1: 227. Eaglewood Cliffs,
New Jersey: Prentice-Hall.
Panchagnula, R., Pillai, O., Nair, V. B. & Ramarao, P. (2000). Transdermal iontophoresis
revisited. Current Opinions in Chemical Biology, 4, 468-473.
Park, Y. S., Ito, Y. & Imanishi, Y. (1998). Permeation control through porous membranes
immobilized with thermosensitive polymer. Langmuir, 14, 910-914.
Parsi, E. J. 1988. Cell for Electrically controlled transdermal drug delivery. U.S. Patent:
4,731,049
Perkins, N., Heard, C. (1999). In vitro dermal and transdermal delivery of doxycycline
from ethanol/migliol 840 vehicles. International Journal of Pharmaceutics, 190,
155-164.
Phipps, J. B. 1991. lontophoresis electrode. U.S. Patent: 5,057,072
Phipps, J. B. 1992. Iontophoresis electrode. U.S. Patent: 5,084,008
Phipps, J. B., Padmanabhan, R. V. & Lattin, G. A. (1989). Iontophoretic delivery of
model inorganic and drug ions. Journal of Pharmaceutical Science, 78, 365-369.

92

Pikal, M. J. (1992). The role of electroosmotic flow in transdermal iontophoresis.
Advanced Drug Delivery Reviews, 9, 201-237.
Prasad, R., Sirkar, K. K. (1988). Dispersion-free solvent extraction with microporous
hollow-fiber modules. AIChE Journal, 44, 177-188.
Reynolds, J. R., Ly, H. & Kinlen, J. 2002. Burst electrode. U.S. Patent Application Pub.
No.: 2002/0022826 Al
Rhodes III, W. E. (2002). Iontophoretic drug delivery: new advantages revitalize an
established technology. Drug Delivery Technology, 2, 34-37.
Riviere, J. E., Heit, M. C. (1997). Electrically-assisted transdermal drug delivery.
Pharmaceutical Research, 14, 687-697.
Roy, S. D., Hou, S. Y., Witham, S. L. & Flynn, G. L. (1994). Transdermal delivery of
narcotic analgesics: comparative metabolism and permeability of human cadaver
skin and hairless mouse skin. Journal of Pharmaceutical Science, 83, 1723-1728.
Sagar, P., Doddayya, H. (2001). Comparison studies of skin permeability of verapamil
HCl transdermal films across mice and human cadaver skin. Indian Drugs, 38,
649-650.
Sanderson, J. E., Deriel, S. R. 1988. Method and apparatus for Iontophoretic drug
delivery. U.S. Patent: 4,722,726
Scott, E. R. 2001. Electrotransport device electrode assembly having lower initial
resistance. U.S. Patent: 6,195,582 B1
Silberstein, W. P. (1997). Fever. Retrieved April 2, 2004 from the World Wide Web:
http://www.mindspring.com/~drwarren/fever.htm.
Siman, J., Dove, J. 2001. Medical devices having improved
antimicrobial/antithrombogenic properties. U.S. Patent: 6,273,875 B1
Singh, P., Maibach, H. I. (1994). Iontophoresis in drug delivery: basic principles and
applications. Critical Reviews in Therapeutic Drug Carrier Systems, 11, 161-213.
SjÖberg, H., Karami, K., Beronius, P. & SundelÖf, L. (1996). Ionization conditions for
iontophoretic drug delivery. A revised pKa of lidocaine hydrochloride in aqueous
solution at 25°C established by precision conductometry. International Journal of
Pharmaceutics, 141, 63-70.
Sloan, K. B., Beall, H. D., Weimar, W. R. & Villanueva, R. (1991). The effect of receptor
phase composition on the permeability of hairless mouse skin in diffusion cell
experiments. International Journal of Pharmaceutics, 73, 97-104.

93

Smith, E., Maibach, H., Eds. (1995). Percutaneous Penetration Enhancers. Boca Raton:
CRC Press.
Suleman, M. I., Doufas, A. G., Akca, O., Ducharme, M. & Sessler, D. I. (2002).
Insufficiency in a new temporal-artery thermometer for adult and pediatric
patients. Anesthesia & Analgesia, 95, 67-71.
Theeuwes, F., Gale, R. & Baker, R. (1976). Transference: A comprehensive parameter
governing permeation of solutes through membranes. Journal of Membrane
Science, 1, 3-16.
Untereker, D. F., Phipps, J. B. & Lattin, G. A. 1992. Iontophoretic drug delivery. U.S.
Patent: 5,135,477
Urquhart, J. 1977. Bandage for transdermally administering scopolamine to prevent
nausea. U.S. Patent: 4,031,894
Urquhart, J. 1981. Method and therapeutic system for administering scopolamine
transdermally. U.S. Patent: 4,262,003
Vander, A. J., Sherman, J. H. & Luciano, D. S. (1994). 6 th Ed. Chapter 18. Human
Physiology: The Mechanisms of Body Function. New York: McGraw-Hill, Inc.
Vernon, B., Gutowska, A., Kim, S. W. & Bae, Y. H. (1996). Thermally reversible
polymer gels for biohybrid artificial pancreas. Macromolecular Symposia, 109,
155-167.
Wang, Y., Fan, Q., Song, Y. & Michniak, B. (2003). Effects of fatty acids and
iontophoresis on the delivery of midodrine hydrochloride and the structure of
human skin. Pharmaceutical Research, 20, 1612-1618.
Welty, J. R., Wicks, C. E. & Wilson, R. E. (1976). 2nd Ed. Fundamentals of Momentum,
Heat, and Mass Transfer. Chapter 30: 634-649. New York: John Wiley & Sons.
Wen, L., Kocherginsky, N. M. (1999). Doping-dependent ion selectivity of polyaniline
membranes. Synthetic Metals, 106, 19-27.
Wilke, C. R., Chang, P. (1955). Correlation of diffusion coefficients in dilute solutions.
AIChE Journal, 1, 264-270.
Yoshida, R., Sakai, K., Okano, T. & Sakurai, Y. (1993). Pulsatile drug delivery systems
using hydrogels. Advanced Drug Delivery Reviews, 11, 85-108.
Zaffaroni, A. 1976a. Microporous drug delivery device. U.S. Patent: 3,993,072
Zaffaroni, A. 1976b. Novel drug delivery device. U.S. Patent: 3,993,073

